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HYPOLIPIDEMIC ACTIVITY OF KUDIKKAI 
SHOORNAM 
The Siddha system of medicine is contributing much more the health 
care of human society. This system is developed by siddhars who are the great 
scientists of ancient days. Generally the siddhars are considered to be super-human 
beings who have defined age and other laws of nature to which all human beings are 
subject to. Siddhars have developed longevity discipline called kayakalpa. Kayakalpa 
is the crown of siddha system as it is not mentioned in any other system of 
medicine.Kaya means body. Kalpa means rejuvenation. It is a legendary system of 
whole body rejuvenation.  
 Kayakalpa has following objectives  
1.Maintaining youthfulness and physical vigor  
2. Withstanding the ageing process and promotes longevity  
3 .Live a full span of quality life  
 The approach is not only towards physical immortality (which on some 
deeper level of harmony may be possible), but the immortality of the mind, the daily 
renewal of brain cells. In such state, the mind and heart are as clear in old age as in 
childhood.  
The medicines that are used to make this, the process of doing, diet to be 
followed; timings to eat all these have been clearly explained by the siddhars in their 
medical scripts.  
Ever since men started curing illness, he began to discover the causes 
for illness. Then prevention of illness was also added in evolution of culture. In his 
efforts to cure and prevent illness he further thought over the postponement of death. 
Siddhars were successful in their research and lived as long as they wished  
 The siddhars were a class of popular writers in Tamil in all its branches 
of knowledge and many of their work were written in what is called high Tamil. The 
kavi or poetry in which the medical and other scientific tracts have been composed is 
much admired by those who have made it their special studies.  
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Kayakalpa has been told by Thirumoolar as  
    
 
    
 
    
 
     
   
Herbal medicine can be used to treat, to enhance treatment or to 
alleviate side effects of other system of medicines. India is one of the largest producer 
of medicinal herbs and is rightly called the “Herbal Garden Of The World.” Rising 
interest in herbal medicine reflects the public’s attempt to create a more gentle 
ecologically sensitive medicine that has been created with technology based medicine.  
Cholesterol, a steroid makes up an important part of the membranes of 
each cell in the body. Our body also uses cholesterol to make bile acid, vitamin D and 
some hormones. Even though it is beneficial, high levels of cholesterol in the blood 
leads to hyperlipidemia a major risk factor for ischemic heart disease and 
cerebrovascular diseases. “Higher the cholesterol greater the risk of Coronary Artery 
Disease”- KD.Tripathi; Medical pharmacology-sixth edition-2010. Faulty diet 
particularly with an increase inclination towards fast food, which are rich in saturated 
fats, lack of exercise, increase time spent on watching TV, increase car ownership, 
increase automation, decrease manual labour in the developing countries are some of 
the reasons  for hyperlipidemia.  
 Cardio vascular disease prevalence in India has risen four-fold in the 
past four decades. Expected to be the leading cause of death and disability by 2020, 
Cardio vascular disease already causes 29% of all deaths in the country. “Indians are 
succumbing to heart disease and stroke in the most productive years of their lives; 
about a decade earlier than their western counterparts” said Dr KS Reddy, President 
of the Public Health Foundation of India.  
With the etiological prominence of hyperlipidemia in Coronary heart 
disease and cerebrovascular disease various drugs have been utilized to lower the 
blood lipids such as clofibrate, niacin, statin and gemfibrozil. All though these drugs 
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were successful in reducing the serum cholesterol levels, they produce unpleasant and 
distressing side effects such as depression, myalgia etc. So a safe and effective herbal 
medicine will provide better result for this condition.  
Kadukkai (Terminalia chebula) is one of the herbal kayakalpa according 
to karuvurar vadha kaviyam. It is a tropical tree which is found growing at attitudes 
upto 650 meters possess a great trunk with thick leaves and has yellowish flowers and 
blackish yellow or blackish-brownish fruits. The fruit is used in medicine, the seed is 
taken out and the whole pulp is used.  
Kadukkai is a rejuvenative, laxative (unripe), astringent (ripe), 
anthelmintic, nervine tonic, expectorant, tonic, appetite stimulant, easily assimilated, 
anti-septic, alterative, diuretic and carminative. It promotes digestive power, heals 
wound and ulcers, cures local swellings, skin diseases, diabetes, chronic and recurrent 
fever, anaemia, diarrhoea, dysentery, cough and dyspnoea. It dispels disease caused 
by vitiation of vatha, pitha and kapha and is useful in spleen enlargement, ascites, 
piles, hoarseness of voice, vomiting and hypertension.  
The major constituents are tannins, chebulagic acid, chebulinic acid, 
ellagic acid, gallic acid, anthraquinones,vit c, chebulic acid, oleic acid, palmitic and 
stearic acid  
Kadukkai has five of 6 tastes, only the saline taste is missing. An 
example of siddha recipe containing kadukkai is Agastiya Rasayana, a famous tonic. 
This formula was created by the sage Agathiyar, the original profounder of siddha 
system of medicine. According to Agathiyar, kadukkai is compared to mother but he 
describes that eventhough kadukkai is compared to mother, it seems to be more than 
mother in the sense, mother feeds the baby and provide nourishment but kadukkai 
drive away the diseases and provides nourishment too.  
 Kadukkai promotes long life, rejuvenates and stimulates enzymatic action. 
Phytosterols and natural antioxidants have also been shown to be effective in reducing 
lipid profiles and also lessen peroxidative modification of lipoproteins and 
atherosclerosis. Since kadukkai contains high amounts of phytosterols, saponins, 
chebulinic acid and corilagen, it will be a promising phytomedicine for hypolipidemic 
activity. In that basis, it will be an excellent drug for hypolipidemic activity. 
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CHAPTER  I 
 
1. Aim : 
 To validate the safety and efficacy of Kadukkai Choornam in the 
management of  Hyperlipidemia. 
2. Objectives: 
               In this dissertation work, the “KADUKKAI CHOORANAM’ is analyzed in 
       the following aspects: 
• Standardization of Kadukkai choornam including pharmacognostic 
characterization of raw drug and purity analyses 
• Safety profile for the test drug in rat 
• Pharmacological study to evaluate the hypolipidemic activity in rat 
• Open clinical study to assess the safety and efficacy of the drug on 
hyperlipidemic patients. 
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CHAPTER II                           REVIEW OF LITERATURE 
1.Drug review 
Botanical aspect of the plant 
Botanical name: Terminalia chebula (Gaertn) Retz 
Classification 
Kingdom : Plantae  
Subkingdom : Tracheobionta 
Superdivision : Spermatophyta  
Division : Magnoliophyta   
Class : Magnoliopsida  
Subclass : Rosidae   
Order : Mirtales  
Family : Combretaceae   
Genus : Terminalia 
Species : chebula  
 
Vernacular names 
 English  : Chebulic Myrobalan  
Tamil : Kadukkai  
Sanskrit : Haritaki, priya, sudha   
Hindi : Pile Hara  
Pers : Haleelai Siah  
Kan : Anile-Kayl  
Tel : Chitti karakkaya 
Mal : Katukkaipinja  
        Hippocrates said that if one bites a piece of Chebulic Myrobalan after meals and 
swallow its juice, one will remain free from all diseases. Kadukkai chewed in the 
morning everyday in empty stomach  heals a number of ailments like piles, colitis, 
skin eruptions, constipation, voice disorders, asthma, defective vision, wounds, 
acidity, gall stones etc. The most important point to remember is that it increases 
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longevity. It is said to be a good liver tonic.  (Ref: Fruit and vegetable juice therapy  - 
N.N.Saha2002) 
Description 
      It is a large deciduous tree 15-24m in height and 1.5 to 2.4m in girth with a 
cylindrical bole of 4-9m, a rounded crown and spreading branches, found throughout 
the greater parts in India. Bark dark- brown often longitudinally cracked, exfoliating 
in woody scales; leaves are mostly sub opposite, ovate or elliptic with a pair of large 
glands at the tip of the petiole: flowers are dull, white or yellow, small scented in 
terminal, paniculate spikes, drupes ellipsoidal, obovoid  or ovoid yellow to orange 
brown, sometimes tinged with red or black and hard when ripe, 3-5cm long, become 5 
ribbed on drying, seeds hard, pale yellow.  Based on fruit size and shape it has as 
many as seven types. Flowering / Fruiting- April to June/January to March. (Wealth 
of India volume 3) 
Parts used- Fruits 
          The mature (ripe) haritaki fruits are harvested during the autumn season, when 
they have the strongest medicinal and laxative effect. Drying the fruit properly in the 
sun to make a powder reduces the laxative effect slightly, and cooking or steaming 
reduces it even further, due to oxidation of the laxative chemicals. Traditional doctors 
disapprove of cooking the fruit when it should be sun-dried (a tedious process). The 
cooking process is thought to weaken the herb's medicinal effectiveness. (Medicinal 
and Aromatic Plants of HP - Narain Singh Chauhan 1999). 
Materia Medica 
          Chebulic myrobalan  fruit embodies all tastes except salt. It is good for health 
and long life. It is also tridosagna, meaning it can be used with any type of health 
imbalance. Furthermore, it is a mild laxative that aids digestion. Kadukkai is used to 
nourish the heart, liver, and kidney, and to treat diseases of the eye, for which it is 
used both internally and externally. 
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Types 
According to siddha it is classified into seven types. They are 
Vijaya: looks just a squash and can be used in any case. 
Rohini: is round in shape and more effective for healing. 
Putana: is small in size with big hard seeds, and is useful for external plastering.  
Amrita: is fleshier, and good for body purification.  
Abhaya: has five lobes, and is more effective for ophthalmic use (external). 
Jivanti: is yellow in colour and good for all cases. 
Chaetaki: has three lobes, is good to use in the form of powder, and is more laxative 
than the others. Chetaki comes in two varieties - white and black. 
 
General character 
           uõøh PÊzuUQ uõ¾ SÔ°Âh¨ 
¥øh ]¼£u•Ø @£v•h® - Bøhö¯mhõz 
 y»ªi ¦sÁõu @ŒõoPõ ©õø»°µs 
hõ»ªi @£õ®Á›UPõ ¯õÀ. 
 
         Kadukkai cures the diseases of the Cheek, neck, tongue and penis. It is said to be 
a potent drug for obesity and cures jaundice, herbal and animal poison. 
         A decoction of chebulic myrobalan is a good astringent. Wash useful in bleeding 
piles and some vaginal discharges. 
         Finely powdered kadukkai is used as a dentifrice useful in carries teeth, bleeding 
and ulceration of gums. 
        Coarsely powdered and smoked in a pine it affords relief in a fit of asthma. 
        Equal parts of kadukkai and kasukatti rubbed into a paste and applied for tongue 
ulcer. 
        Unriped fruit is rubbed with milk given internally for cough. 
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        In folk medicine, kadukkai is used in constipation, tympanitis, vomiting, colic, 
sprue syndrome, jaundice, splenic disorders, for treating cough, asthma, hiccup, throat 
affections, and impaired voice. 
        One fruit of kadukkai (Terminalia chebula), two fruits of thantrikkai (Terminalia 
bellerica), and four fruits of nellikkai (Emblica officinalis) taken together, were called 
Triphala. It is prescribed as a laxative, digestive, promoter of eyesight, intellect and 
longevity.  It is credited with the properties which  enhance body  resistance against 
diseases and induce immunity; and is included as an adjunct in a number of 
compound preparations. 
       The main purgative ingredient of Triphala is T.Chebula, possibly by rendering 
the irregular peristaltic movements uniformly progressive. The purgative principle in 
the pericarp of the fruit of T.chebula has been found to be a glycoside which may be 
similar to    sennoside  A (Wealth of India) 
       The presence of a non-nitrogenous neutral principle in the fruit, named chebulin, 
possessing anti spasmodic activity similar to that of papaverine has been reported 
(Gaind et. al, Indian J Pharm,1964,26,10) 
       Triphala is used in folk medicine, as a dentrifrice for bleeding gums. Mixed with 
oil, it is applied to cuts, wounds, burns and scalds. Water, in which Triphala has been 
steeped overnight, is used as a cooling wash for eyes. Also for affording relief in 
conjunctivitis. 
         Triphala  also used as adjunct to other medicines in numerous disease. 
         Haritaki fruit contains anthraquinone - like (laxative) chemicals as well as 
tannins and astringents (reported in Kapoor, 1990). To bring out these opposing 
actions within a given product, siddha doctors administer it with warm water to 
strengthen the laxative action, and with ice cold water to promote the astringent 
action. For example, the juice mixed with cold water can be used as a mouthwash to 
treat spongy gums. 
       The post - digestive or delayed reaction of haritaki fruit (vipaka) is very strongly 
nourishing, so this is an excellent choice as a laxative in weak or elderly patients. 
[One earth herbal source book - Herbalist Alan Tilotson] 
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         Haritaki fruit is part of triphala, the three-fruit formula. It is generally 
administered in triphala form rather than by itself to draw upon the tonic effects. Each 
of the triphala fruits is tonic, and together they act to balance the three primary 
balancing forces, Vata, Pitta and Kapha.  
        Dried or cooked haritaki fruit  tighten up the stool for chronic diarrhoea and 
dysentery. By stating that it can be used for both hot and cold patterns of disease, they 
are acknowledging the balanced action of this herb. 
ACTIVE PRINCIPLES AND PHARMACOLOGY 
       Fruit contain chebulinic acid, tannic acid and chebulin.  Oil from kernels yielded 
palmitic, searic, oleic, linoleic, arachidic and behenic acids.   
      Antioxidant constituents of the plant, phloroglucinol and pyrogallol, have been 
isolated along with ferulic, vanillic, p-coumaric and caffeic acids.  Acid esters present 
in phenolic fraction of extract were found more effective. 
       A new ellagitannin-terchebulin-has been isolated from fruits along with 
punicalagin and terflavin A and its structure has been elucidated.  Terflavins B, C and 
D, punicalagin and punicalin have been isolated from leaves. 
       Gallic, triacontanoic and palmitic acids, beta-sitosterol, doucosterol, ethyl ester of 
gallic acid from fruits have been isolated.  A new triterpene - chebupentol-has been 
isolated from fruits; arjungenin, terminoic acid arjunolic acid have been isolated. 
        The oil in the kernel increased the motility of the gastrointestinal tract of the 
mouse. The action was comparable with castor oil.  The oil itself is non irritant, but 
releases an irritant principle when incubated with lipase. (Indian herbal remedies 
C.P.Khare 2004) 
  Research Highlights 
• kadukkai fruit extract was tested as a mouth rinse to study its effect on 
bacterial growth. It significantly inhibited salivary bacterial count and total 
streptococcal mutans  count (Jagtap and Karkera, 1999). 
• Kadukkai  fruit was one of six traditional herbs administered to animal to test 
their adaptogenic potential. All six traditional rasayana plants were able to aid 
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the animals against a variety of different stressors working in different ways 
(Rege, 1999). 
• Alcohol extract of chebulic myrobalan was tested in vitro against several 
pathogenic and opportunistic microorganisms. It had a broad spectrum as well 
as potent action. Subsequent animal testing showed no cellular toxicity 
(Ahmad et al., 1998). 
• Tests of alcohol extracts revealed gallic acid and its ethyl ester, two potent 
antimicrobial substances that acted against even resistant strains of 
Staphylococcus aureus (Sato et al., 1997) 
Chebulic myrobalan significantly reduced the viral loads in a chronic lung 
infection (CMV) which is common in AIDS patients (Yukawa et al., 1996). 
• Haritaki fruit was one of four herbs screened out for potency to test for use 
with the anti-viral drug acyclovir against herpes (HSV-1) in a study at the 
Toyama Medical and Pharmaceutical University in Japan. When acyclovir was 
combined with any one of  the herbal extracts and ingested in oral doses 
similar to human use, the results were significantly stronger than the use of the 
drug or the herbs alone, especially reducing viral loads in the brains of the 
animals (Kurokawa et al., 1995). 
Current scenario of research in Kadukkai 
Antioxidant Effects of Aqueous Extract of Terminalia chebula in Vivo and in 
Vitro 
 The objective of this study was to evaluate the protective effects of an 
aqueous extract of fruit of T. chebula on the tert-butyl hydroperoxide (t-BHP)-induced 
oxidative injury observed in cultured rat primary hepatocytes and rat liver. Both 
treatment and pretreatment of the hepatocytes with the T. chebula extract (TCE) 
significantly reversed the t-BHP-induced cell cytotoxicity and lactate dehydrogenase 
leakage. ( Hyun-Sun LEE, et, al) 
Inhibition of cancer cell growth by crude extract and the phenolics of 
Terminaliachebula retz. Fruit Journal of Ethnopharmacology  
            A 70%methanol extract of Terminalia chebula fruit, was studied for its effects 
on growth in several malignant cell lines including a human (MCF-7) and mouse 
(S115) breast cancer cell line, a human osteosarcoma cell line (HOS-1), a human 
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prostate cancer cell line (PC-3) and a non-tumorigenic, immortalized human prostate 
cell line (PNT1A) using assays for proliferation ([H]-thymidine incorporation and 
coulter counting), cell viability (ATP determination) and cell death (flow cytometry 
and Hoechst DNA staining). In all cell lines studied, the extract decreased cell 
viability, inhibited cell proliferation, and induced cell death in a dose dependent 
manner. (1 August 2002, Pages, Ammar Saleem et.al) 
Antibacterial activity of black myrobalan (Terminalia chebula. Retz) against 
Helicobacter pylori, International Journal of Antimicrobial Agents, Volume 18, 
Issue 1, July 2001, F Malekzadeh , et, al 
• The effect of ether, alcoholic and water extracts of black myrobalan 
(Teminalia chebula. Retz) on Helicobactor pylori  were examined using an 
agar diffusion method on Columbia Agar. Water extracts of black myrobalan 
showed, significant onantibacterial activity and had a minimum inhibitory 
concentration (MIC)  
Influence of Terminalia chebula on dermal wound healing in rat 
Lonchin Suguna, et, al  T. chebula treated wounds healed much faster as indicated by   
improved rates of contraction and a decreased period of epithelialization. Biochemical 
studies reveled a significant increase in total protein, DNA and collagen contents in 
the granulation tissues of treated wounds.  
Journal of health science 
Anti-Diabetic Activity of Fruits of Terminalia chebula on Streptozotocin Induced 
Diabetic Rats  
            Oral administration of ethanolic extract of the fruits (200 mg/kg body 
weight/rat/day) for 30 days significantly reduced the levels of blood glucose and 
glycosylated hemoglobin in diabetic rats. ( Gandhipuram  et al.,)  
Antioxidant and Free Radical Scavenging Activities of Terminalia chebula          
Free radicals react with biological molecules and destroy the structure of cells, which 
eventually causes free-radical induced disease such as cancer, renal failure, aging, etc. 
The results showed that all tested extracts and pure compounds of  T. chebula 
exhibited antioxidant activity at different magnitudes of potency.( Hua-Yew Cheng, 
et, al) 
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Medicinal preparations of Kadukkai 
1.Kadukkai nei 
Kadukkai - 100gm 
Keezhkai nelli - 700gm 
       Kadukkai, keezha nelli are crushed and  decoction is prepared. Katakarogini, 
kadukkai, thippili each 17.5gm, are ground and add with above decoction.Then ghee 1 
padi is added, boiled and filtered. 
Dose : 10.2 gm twice daily. 
Uses : Obesity, indigestion, constipation, pitham. 
Ref :  Pathinen  Siddhar Arulia Aavialikum Amutha Murai Churukkam, 
V.Kanthaswamy Muthliar 
2.Kadukkai Karpam 
Prepararation : Kadukkai is powdered finely and bottled. 
Dose : 1gm twice daily 
Uses:                  Jaundice precaution 
3.Kadukkai Legium 
Preparation:  Kadukkai 350 gm crushed.Water two marakkal to be added, boiled,                         
reduced to 1/8 part and the decoction is strained in a vessel. 350 gm 
sugar is dissolved and boiled into a syrup. In that sivadhai, ginger, 
pepper, omam vaividangam ,thippili each 35gm ground well and 
added. Ghee 1padi added and mixed in order to make the consistency 
of the medicine as that of legium. 
Dose : 5gm twice daily 
Uses : Constipation, flatulence, piles, 
17 
 
Other medicines which containing Kadukkai   
Komoothira Silasathu parpam 
Preparation : Kadukkai, thantrikkai nellimulli each 35gm taken. Water 4 saer 
added,  
  boiled and reduced into 1/4 part. 1/4 saer silsathu is rubbed in a 
kalvam,  
  villais are made dried and subjected to putam with 1000 varaties. It  
  become a fine parpam. 
Uses : Tuberculosis, chronic fever. 
Ref : Sarabendira vaidhya rathnavali  
Karpoora Siasathu Choornam 
Preparation :  
        Paereechu - 48gm 
        Nelliparuppu - 48gms 
        Thippili - 48gms 
        Karrpoora silasathu - 48gms 
        Ealam - 48gms 
        Athimathuram - 48gms 
Kadukkai - 48gms 
Vengaram - 48gms 
Sandanam - 48gms 
Vellari vidai - 48gms 
Thania vidai - 48gms 
All the above drugs are powdered and sieved 
Dose : 1/2gm twice daily 
Uses : Mega diseases, ratha pramium, seezh pramium 
Ref : Agathiyar attavanai vagadam 
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Amalathi Girutham 
Amla juice  - 1padi, 
Sugarcane juice - 1padi 
Ghee - 350gms 
Kadukkai powder - 87gms 
Preparation 
 Kadukkai is powdered and rubbed nicely with the help of any one of the above juice. 
All are mixed well in a mud pot boiled until to get the correct consistency  
Dose : Two tea spoon, two times a day. 
Uses : Ulcer, Vomiting, Burning chest. 
Ref : Sihicha Rathna Deepam 
2.Disease review-Obesity 
        Obesity is an abnormal accumulation of body fat, usually 20percent or more over 
an individual`s body weight. (1) Discrepancy between energy consumption and the 
energy expenditure ended up with accumulation of fat. A continuous intake of 50 to 
200 calories extra per day would lead to weight gain of 2-20kg over a period of 4-10 
yrs. Given the cumulative effects of subtle energy, excess body fat content shows 
`tracking` with age such as obese children usually become obese adults. 
           Some reasons for increasing prevalence of obesity are increased energy intake, 
increased portion sizes, increased snacking and loss of regular meals, increased 
energy dense food, increased affluence.  
Decreased energy expenditure 
          Increased car owner ship, decreased walking to school, increased automation, 
decreased manual labour, decreased sports in schools, increased time spent on 
computer games and watching TV.  
           A  few rare single gene disorders have been identified which lead to severe 
childhood obesity. These include mutations of the melanocortin-4receptor (MC4R) 
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that accounts for approximately 5% of severe early-onset of obesity Mutations in the 
leptin gene.  
Reversible  Causes of Obesity 
             Endocrine factors such as hypothyroidism, cushings syndrome, insulinoma, 
hypothalamic tumours or injury.  
Measurement of obesity 
              Severity of obesity can be quantified using the BMI. A waist circumference 
of >102cm in men or >88cm in women indicates that the risk of metabolic and 
cardiovascular complications of obesity is high. 
Quantifying obesity with body mass index 
BMI(kg/m) Classification  Risk of obesity comorbidity 
18.9-24.9 Normal range Negligible 
25.0-29.9 Over weight Mildly increased 
>30.0 Obese  
30.0-34.9 ClassІ Moderate 
35.0-39.9 ClassІІ Severe 
>40.0 ClassІІІ Very severe 
[1] 
                  Hyperlipidemia-is major risk factor for atherosclerosis; even in the 
absence of other factors, hypercholesterolemia is sufficient to stimulate lesion 
development. The major component serum cholesterol associated with increased risk 
is low density lipoprotein (LDL) cholesterol (“bad cholesterol”). LDL cholesterol is 
the form of cholesterol that is delivered to peripheral tissue. In contrast, high density 
lipoprotein (HDL, “good cholesterol”) mobilizes cholesterol from tissues and 
transport it to the liver for excretion in the bile. Consequently, higher levels of HDL 
correlate with reduced risk. High dietary intake of cholesterol and saturated fats 
(present in egg yolks animal fats and butter, for example) raises plasma cholesterol 
levels. Conversely, diets low in cholesterol and with higher ratios of poly unsaturated 
fats lower plasma cholesterol levels.  Omega 3fatty acids (abundant in fish oils ) are 
beneficial, whereas trans-unsaturated fats produced by artificial hydrogenation of 
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polyunsaturated oils (used in baked goods and margarine) adversely affect cholesterol 
profiles. Exercise and moderate consumption of ethanol raise HDL levels, whereas 
obesity and smoking lower it. (Robbins and cotran pathology of disease)   
           Dietary lipids are absorbed in the intestine with the help of bile acids.  
Chylomicrons are formed and passed into lacteals - reach blood stream via thoracic 
duct. During their passage through capillaries, the endothelium bound lipoprotein 
lipase hydrolysis the TGs into fatty acids which pass into muscle cells  to be utilized 
as energy source and  in fat cells to be reconverted into TGs and stored.  The 
remaining part – chylomicron  remnant containing mainly cholesterol ester and little 
TG engulfed by liver cells, which have receptors for the surface apoproteins of 
chylimicron remnant and digested.  Free cholesterol that is liberated is either stored in 
the liver cells after reesterification or incorporated into a different lipoprotein and 
released in blood  or excreted in bile as cholesterol /bile acids 
          Liver secretes very low density lipoprotein (VLDL) containing mainly TG and 
some cholesterol ester and some cholesterol into blood.  VLDL is acted upon by 
endothelial lipoprotein lipase  in the same way as on chylomicrons and the fatty acids 
pass into the adipose tissue and muscle; the remnant called intermediate density 
lipoprotein (IDL) now contains more cholesterol esters than triglycerides.  About half 
of the IDL is taken back by the liver cells by the attachment to another receptors 
(LDL receptor), while the rest loses the remaining triglycerides gradually and 
becomes low density lipoprotein (LDL) containing only clolesterol ester.  The LDL 
circulates in plasma for a long time; its uptake into liver and other tissues is dependent 
on the need for cholesterol.  The rate of LDL uptake is regulated by the rate of  LDL 
receptor synthesis in a particular tissue. 
             The cholesterol ester of LDL  is de-esterified and used mainly for cell 
membrane formation.  The cholesterol released into blood from degradation of 
membranes is rapidly incorporated in high density lipoprotein (HDL), esterified with 
the help of an enzyme lecithin. The excess lipoproteins in plasma are phagocytosed by 
macrophages for disposal. when too much of lipoproteins have to be degraded in this 
manner. Cholesterol  is deposited in atheroma (in arterial walls) and xanthomas (in 
skin and tendons)- (Tripathy)   
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CHAPTER III      MATERIAL AND METHODS 
 
1. STANDARDIZATION OF KADUKKAI CHOORNAM 
1.1 Collection and authentication of raw drug: 
Fresh fruits of Kadukkai were collected during the month of June (2012) 
from Kollimalai, Salem Dist, Tamilnadu, India and dried well. The dried raw drug 
was authenticated by the botanist, Siddha Central Research Institute, Chennai and also 
from the experts in the Department of PG Gunapadam, Govt. siddha medical college, 
Chennai-106 by correlating the macroscopic characters with the specimen kept in the 
department.  
1.2 Macroscopic and microscopic studies of test drug 
 Outer Coat  
For examining the outer coat, 3 fruits were boiled in caustic alkali 
solution in a test tube for 1-2 minutes. After boiling, the pieces were placed on slide, 
the layers of the coat were removed and examined them after mounting in glycerol 
solution. 
Sectioning 
The pericarp of the fruits were boiled for 15 minutes and cut into small 
peices for examining purpose. Then, it was fixed in FAA (Formalin-5ml+ Acetic 
acid-5ml + 70% Ethyl alcohol-90ml). After 24 hrs of fixing, the specimens were 
dehydrated with graded series of tertiary – Butyl alcohol as per the schedule given by 
Sass, 1940. Infiltration of the specimens was carried by gradual addition of paraffin 
wax (melting point 58-60 C) until TBA solution attained super saturation. The 
specimens were cast into paraffin blocks. The paraffin embedded specimens were 
sectioned with the help of Rotary Microtome. The thickness of the sections was 10-
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12 μm. Dewaxing of the sections was done by customary procedure (Johansen, 1940). 
The sections were stained with Toluidine blue as per the method published by 
O’Brien et al (1964). Since, Toluidine blue is a polychromatic stain, the staining 
results were remarkably good; and some cytochemical reactions were also obtained. 
The dye rendered pink colour to the cellulose walls, blue to the lignified cells, dark 
green to suberin, violet to the mucilage, blue to the protein bodies etc. wherever 
necessary sections were also stained with safranin and Fast-green and IKI(for 
Starch). 
Photomicrographs 
Microscopic descriptions of tissues are supplemented with micrographs 
wherever necessary. Photographs of different magnifications were taken with Nikon 
lab photo 2 microscopic Unit. For normal observations bright field was used. For the 
study of crystals, starch grains and lignified cells, polarized light was employed. Since 
these structures have bi refringent property, under polarized light they appear bright 
against dark background. Magnifications of the figures are indicated by the scale-bars. 
Descriptive terms of the anatomical features are as given in the standard Anatomy 
books (Esau, 1964). 
1.3 Preparation of Kadukkai choornam 
 Kadukkai choornam was prepared by the method described in 
page no. 207, Siddha Materia Medica – Medicinal plants division (Murugesha 2008). 
The pericarp of Kadukkai fruits were collected by removing the seeds. The well dried 
pericarps were made into very fine powder by grinding in pulveriser and filtered 
through the mesh of the sieve size no. 125. The fine powder was subjected for 
purification by the pittaviyal method.  The powder was moistened with cow’s milk. 
The pot was half filled with milk and water. The mouth of the pot was covered with 
24 
 
white cotton cloth. The powder (moistened by milk) was placed above the cloth. The 
mouth of the pot closed with another mud pot. The gap between the two mud pots was 
tied with a wet cloth to avoid evaporation. Then, this arrangement was put on fire and 
boiled until water level gets reduced in the lower pot. Then, the powder was taken out, 
and dried, and powdered finely, and preserved in an air tight container. The expiry 
period of Kadukkai choornam has been for 3 months. It should be used within that 
period. 
1.4 Physico chemical analyses 
1.4(a) Physico chemical parameters  
Determination of Total Ash 
 3 g of the powder was incinerated in a silica dish at a temperature not 
exceeding 450º until free from carbon, cool and weigh. The percentage of ash was 
calculated with reference to the air-dried drug. 
Determination of Acid Insoluble Ash 
The obtained ash was boiled for 5 minutes with 25 ml of dilute 
hydrochloric acid and insoluble matter was collected in ashless filter paper. Then, it 
was washed with hot water and ignited to constant weight. The percentage of acid-
insoluble ash was calculated with reference to the air dried drug. 
Determination of Alcohol Soluble Extractive 
5 g of powder was mixed with 100 ml of Ethanol of the specified 
strength in a closed flask and kept alone for twenty-four hours.  Filtered rapidly with 
taking precautions against loss of solvent.  25 ml of the filtrate was evaporated to 
dryness in a tared flat bottomed shallow dish, and dried at 105º, to constant weight 
and weighed. The percentage of alcohol-soluble extractive was calculated with 
reference to the air-dried drug. 
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Determination of Water Soluble Extractive 
5 g of powder was mixed with 100 ml of chloroform water of the 
specified strength in a closed flask and kept alone for twenty-four hours.  Filtered 
rapidly with taking precautions against loss of solvent.  25 ml of the filtrate was 
evaporated to dryness in a tared flat bottomed shallow dish, and dried at 105º, to 
constant weight and weighed. The percentage of water-soluble extractive was 
calculated with reference to the air-dried drug. 
Determination of Moisture Content (Loss on Drying) 
10 g of drug was taken in the tared evaporating dish and dried at 105º 
for 5 hours, and weighed. (Continue the drying and weighing at one hour interval until 
difference between two successive weighing corresponds to not more than 0.25 per 
cent. Constant weight is reached when two consecutive weighing after drying for 30 
minutes and cooling for 30 minutes in a desiccator, show not more than 0.01 g 
difference). 
Potential of Hydrogen (pH) 
 The pH scale is logarithmic and runs from 0.0 to 14.0 with 7.0 being 
neutral. Readings less than 7.0 indicate acidic solutions, while higher readings 
indicate alkaline or base solutions.  
1.4(b) THIN LAYER CHROMATOGRAPHY 
Solvent system 
Toluene : Ethyl acetate: Acetic acid  (5 : 5 : 0.5). 
TLC plate 
  Aluminium plate precoated with silica gel 60F254 of 0.2 mm thickness 
(Merck). 
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Developing chamber 
 Camag’s twin trough chamber. 
Visualizing reagent 
 Vanillin-sulphuric acid reagent. 
Extract Preparation 
4 g of the chooranam was soaked overnight in chloroform. Boiled on a water 
bath for 10 mins, filtered and concentrated to 10 ml.  
Procedure 
 The extract was applied on the TLC using capillary and developed in the 
solvent system.  The developed TLC plate was air dried and photograph was taken in 
white light. Then dipped in vanillin-sulphuric acid reagent, heated in an oven at 
105°C until the development of coloured spots and photograph taken. 
1.4 (c). Qualitative Phytochemical Analysis: 
S.No EXPERIMENT OBSERVATION INFERENCE 
1. Test for Alkaloids: Alkaloids 
are identified by precipitate 
method 
Dragendroff’s reagent: 
An aqueous plant extract 
of 2 ml is mixed with 2 ml 
of Dragendroff’s reagent. 
 
Absence of reddish 
brown precipitate 
 
Absence of 
alkaloids 
2. Test for Triterpenoids 
(Noller’s Test) 
To few mg of extract, add tin 
and thionyl chloride and heat 
in water bath. 
       
 Absence of purple 
colour 
 
 
Absence of  
Triterpenes 
3. Test for Tannins:A plant 
sample dried powder 0.5 gm is 
boiled in 20 ml of water and 
 
Forms a brownish-
green or bluish- black 
 
Presence of 
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filtered. The filterate 2 ml is 
taken and 3-5 drops of Fecl2  
(0.1%) is slowly added to it. 
colour. Tannins 
4. Test for Flavonoids: An 
aqueous filterate of plant 
sample is mixed with 5 ml of 
dilute Ammonium solution and 
few drops of concentrated 
H2SO4  is slowly added through 
the sides of the test tube. 
 
Absence of  Yellow 
colour formed 
 
Absence of 
flavonoids 
6. Test for Glycosides:An 
aqueous plant extract of 2 ml is 
added with 1 ml of 
concentrated Hcl and boiled in 
a water bath for about 2 hours. 
The filtrate is separated and 3 
ml of chloroform is added, 
then 10% of 1ml Ammonium 
solution is added.  
Absence of pink colour 
formation 
Absence of 
glycosides 
7. Test for Saponin: A 
powdered 2 gm of plant 
sample is boiled with 20 ml of 
distilled water, then filtered, 
the filterate is added with fresh 
5 ml of distilled water and 
shaken vigorously. 
A permenant or 
persistant froth is 
formed.The froth is 
turned in to emulsion 
by adding three drops 
of olive oil. 
Presence  of 
saponin 
8. Test for Phenolic 
compounds: 
  About 2 ml of aqueous plant 
extract is mixed with 2 ml of 
Fecl3 solution.  
Presence of deep bluish 
green colour  
Presence of 
phenolic 
compounds 
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Methodology for Chemcial Analysis 
Preparation of Extract : 
Add 5 gm of the sample to 50ml of distilled water. Boil the solution for 20 minutes, 
cool and then filter. Use the Extract for the following tests. 
S.No Experiment Observation Inference 
1. Test for reducing Sugar : 
To 5ml of Benedicts qualitative 
reagent, add 10 drops of extract, 
then boil for two minutes 
Green / Yellow / 
Red PPT 
Presence of 
Reducing Sugar 
2. Test for Starch : 
To 5 ml of extract add 2ml of 
acetic acid and then add few drops 
of N/50 Iodine Solution. 
Blue Colour Presence of 
Starch 
3. Test for Proteins : 
To 2 ml of extract, add 2ml of 5% 
Sodium Hydroxide mix and add 2 
drops of Copper Sulphate 
Solution. 
Violet or Purple 
Colour 
Presence of 
Proteins 
4. Test for Amino Acid : 
Place  2 drops of extract on a filter 
paper and allow to dry well. Then 
spray 1% ninhydrin over the same 
and allow to dry. 
Violet Colour Presence of 
Amino Acid 
5. Test for Albumin : 
To 2 ml of extract, add 2ml of 
Esboch’s reagent. 
Yellow PPT Presence of 
Albumin 
6. Test for Phosphate : 
To 2ml of extract, add 2ml of 
ammonium Molybdate solution 
and 2ml of concentrated Nitric 
Yellow PPT Presence of 
Phosphate 
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Acid. 
7. Test for Sulphate : 
To 2 ml of extract add 2ml of 4% 
ammonium oxalate solution. 
White PPT Presence of 
Sulphate 
8. Test for Chloride :  
Add 2ml of extract to dilute nitric 
acid till the effervescence ceases. 
Then add 2 ml of Silver Nitrate 
Solution. 
Cloudy White PPT Presence of 
Chloride 
9. Test for Iron : 
To 2ml of extract, add 2ml of 
ammonium thio cynate solution 
and add 2ml of concentrated 
Nitric Acid. 
Red Colour Presence of Iron 
10. Test for Calcium : 
To 2 ml of extract, add 2 ml of 4% 
ammonium Oxalate Solution. 
White PPT Presence of 
Calcium 
11. Test for Sodium : 
Make a paste with 2 pinches of the 
sample with Hcl and Introduce it 
into the blue flame.  
Yellow Flame Presence of 
Sodium 
12. Test for Potassium : 
Add a pinch of the sample to 2 ml 
of Sodium Nitrate Solution. Then 
add 2ml of Cobal Nitrate in 20% 
acetic acid. 
Yellow PPT Presence of 
Potassium 
13. Test for Zinc : 
To 2ml of extract, add few drops 
of Sodium Hydroxide. 
 
White PPT Presence of Zinc 
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14. Test for Magnesium : 
To 2ml of extract, add few drops 
of Sodium Hydroxide Solution 
White PPT Presence of 
Magnesium 
15. Test for Alkaloids : 
a. To 2ml of extract, add 2ml 
of Potassium Iodide 
Solution 
b. To 2ml of extract add 2ml 
of Picric Acid. 
c. To 2 ml of extract add 2ml 
of Phosphotunqstic Acid. 
 
Red Colour 
 
 
Yellow Colour 
 
White PPT 
 
Presence of 
Alkaloids 
 
Presence of 
Alkaloids 
Presence of 
Alkaloids 
16. Test for Tannic Acid : 
To 2ml of extract add 2 ml of 
Ferric Chloride Solution 
Black PPT Presence of 
Tannic Acid 
 
1.4 (d) FOURIER TRANSFORM INFRARED SPECTROSCOPY (FTIR): 
INSTRUMENT DETAILS: 
Model : Spectrum one: FT-IR Spectrometer  
Scan Range : MIR 450-4000 cm-1  
Resolution : 1.0 cm-1  
Sample required : 50 mg, solid or liquid. 
 Fourier Transform Infrared Spectroscopy (FTIR) is an analytical 
technique used to identify mainly organic materials. FTIR analysis results in 
absorption spectra which provide information about the chemical bonds and 
molecular structure of a material. The FTIR spectrum is equivalent to the 
"fingerprint" of the material and can be compared with cataloged FTIR spectra to 
identify the material. 
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Infrared spectrum is useful in identifying the functional groups like -OH, -CN, 
-CO, -CH, -NH2, etc. Also quantitative estimation is possible in certain cases for 
chemicals, pharmaceuticals, petroleum products, etc. Resins from industries, water 
and rubber samples can be analyzed.  
1.4(e) SCANNING ELECTRON MICROSCOPE (SEM): 
The Scanning Electron Microscope (SEM) is a microscope that was electrons 
rather than light to form an image. There are many advantages to using the SEM 
instead of a light microscope. 
Resolution : 1.2 nm gold particle separation on a carbon substrate 
Magnification : From a min of 12 x to greater than 1, 00,000 X 
The SEM has a large depth of field, which allows a large amount of the 
sample to be in focus at one time. The SEM also produces images of high resolution, 
which means that closely spaced features can be examined at a high magnification. 
Preparation of the samples is relatively easy since most SEM one require the sample 
to be conductive. 
The combination of higher magnification, larger depth of focus, greater 
resolution, and easy of sample observation marks the SEM one of the most heavily 
used instruments in research areas today. 
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2. TOXICOLOGICAL AND PHARMACOLOGICAL STUDIES 
2.1 Experimental Animals  
 Wistar albino adult male rats weighing 200-350gm from animal housing 
facility of Vels University, were housed in polypropylene cages maintained with 
temperature 27°C ±1°C and 12 hrs light and dark cycles. The animals were allowed to 
acclimatize to the environment for one week and supplied with a standard pellet diet 
(Sai durga foods, Bangalore). The experimental protocol used in this study was 
approved by IAEC. (XIII/VELS/PCOL/10/2000/CPCSEA/IAEC/08.08.2012). 
2.2 Acute Toxicity study 
Acute oral toxicity was conducted as per the OECD guidelines 423-2001 (Acute 
Toxic Class Method) and Ecobichon (1997). 
2.3 Screening the efficacy of Kadukkai Choornam on Triton induced 
hyperlipidemic rat 
Procedure 
 Wistar rats weighing 200–350 g were starved for 18 h and then injected 
intravenously with 200 mg/kg Triton WR 1 339 (isooctyl-polyoxyethylene phenol). 
Serum cholesterol levels increase sharply 2–3 times after 24 h (phase I). The 
hypercholesterolemia decreases nearly to control levels within the next 24 h (phase 
II). The test drugs employed or the solvent for the controls are administered 
simultaneously with the Triton injection or 22 h thereafter. Serum cholesterol analyses 
are made 6, 24, and 48 h after Triton injection. The mechanism of the Tritoninduced 
hypercholesterolemia in phase I is thought to be due to increased hepatic synthesis of 
cholesterol through the ability of Triton to interfere with the uptake of plasma lipids 
by the tissues. Drugs interfering with cholesterol biosynthesis were shown to be active 
in phase I, while drugs interfering with cholesterol excretion and metabolism were 
active in phase II.  
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 Experimental protocol 
The animals were divided into five groups of six rats each. Group I 
served as normal control administered with 2% CMC only. Group II served as 
Hyperlipidemic Control administered with a single dose of triton 400 mg/kg. Group 
III and IV served as test groups received KC 250mg/kg and KC 500mg/kg 
respectively with triton administration. Group V served as standard treated with 
Lovastatin (10mg/kg/day) and Triton administration.  All the animals after 72 hours 
of triton injection (ie. after inducing hyperlipidemia) the respective treatment was 
continued for 7 days.  
 Collection of blood  
 On the 8th day the blood was collected by retro orbital sinus puncture, 
under mild ether anaesthesia. The collected samples were centrifuged for 10 minutes. 
Then serum samples were collected and it is used for various biochemical 
experiments. Then animals were sacrificed and collected the liver. 
 Liver lipid extraction  
 The liver was homogenized in cold 0.15M KCl and extracted with 
CHCl3: CH3OH (2% v/v). This lipid extract was used for the estimation of lipid 
parameters.  
Biochemical analysis  
 The serum and liver were assayed total cholesterol, triglycerides, 
phospholipids, high-density lipoprotein (HDL), low-density lipoprotein (LDL), very 
low-density lipoprotein (VLDL). The serum cholesterol levels were determined using 
semi auto analyser. The triglyceride, phospholipids, serum HDL, LDL and VLDL was 
calculated by using standard methods.  
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3. CLINICAL STUDY OF KADUKKAI CHOORNAM 
3.1 Objectives 
`The study was conducted on hyperlipidemic patients to assess the 
hypolipidemic activity of “KADUKKAI  CHOORANAM” clinically, both in-patients 
and outpatients of both sex and varying age groups. 
3.2 Study Centre 
The clinical study for HYPERLIPIDEMIA is carried out in outpatient 
department and in patient ward of Govt.Siddha medical college hospital and Arignar 
Anna Indian Hospital, Arumbakkam, Chennai-106. 
3.3 Design of the study: 
Open clinical trial, phase II B 
3.4 Selection: 
50 patients from both sexes of various age groups were selected for 
clinical trial. Among 50 patients, 40 patients were treated as out-patients, 10 patients 
were treated as in– patients. The selection was based on the including and excluding 
criteria. They were clinically diagnosed on the basis of siddha principles with modern 
laboratory findings. 
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3.5 Registration Process 
To register a patient, the following documents has been proceded. 
¾ Copy of required laboratory tests 
¾ Signed patient consent form then I verified eligibility and assigned a patient 
study number, drug dose and registered the patient on the study. 
3.6 Selection Criteria: 
Inclusion Criteria 
¾ Sex: Both Male and female patient 
¾ Age: 20 – 65 years 
¾ BMI more than 25.  
¾ Abdominal circumference more than 85 for females and more than 102 for 
males. 
¾ Total cholesterol level more than 180mg/dl to 300 mg/dl, Triglycerides more 
than 150 mg%, LDL more than 100 mg%. Any one of the above parameter 
should be present to include in the trial.  
¾ Patients who were willing to give consent 
Exclusion Criteria 
¾ Children, Pregnant women, elder subject more than 65 year 
¾ Concurrent illness such as Diabetes mellitus type2, Nephrotic syndrome, Hypo 
thyroidism, Congestive cardiac failure, recent history of IHD 
¾ Total cholesterol level more than 300 mg/dl 
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3.7 Criteria for withdrawal: 
Patients were removed from study when any of the criteria listed below applies.In 
the absence of treatment delays due to adverse events, treatment may continue for 2 
cycles or\ until one of the following criteria applies: 
¾ Disease progression, 
¾ Deterioration of vital signs with cardiac, respiratory, hepatic, renal and CNS 
changes. 
¾ Intercurrent illness that prevents further administration of treatment, 
¾ Unacceptable adverse event(s), 
¾ Patient decides to withdraw from the study, or 
¾ General or specific changes in the patient’s condition render the patient 
unacceptable for further treatment in the judgment of the investigator. 
3.8 Investigations: 
For all the cases full clinical data were recorded and they were 
diagnosed on the basis of SIDDHA principles i.e.  Envagai Thrvugal,  Ezhu Udal 
Thathukkal etc. All the patients under study were subjected to blood investigations for 
TC, DC, ESR,  Hb, Blood urea,  Blood sugar .and lipid profile were done. Urine test 
for albumin, sugar, deposits and motion test for ova, cysts were done. 
3.9 Routine examination and assessment 
The full details of history and physical examination of the patients were 
recorded as per the proforma. The clinical assessment was done initially at the end of 
7 days, 14 days and 21 days during treatment and at the end of the 21 days follow up 
were done. The laboratory investigation and the physiological parameters will be 
recorded initially and the end of the treatment and at follows up as per the Proforma. 
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3.10 Mode of administration of the test drug: 
Form of the medicine : Chooranam 
Route of Administration : Enteral 
Dose : 1gm 
Anubanam (Vehicle) : Warm water 
Times of Administration : Two times a day; before food 
Duration : 7 weeks 
3.11 Diet and Medical Advice: 
Do’s 
¾ Decrease portion size 
¾ Decrease energy dense food 
¾ Lot of vegetables 
¾ Exercise 
¾ Plenty of water 
Dont’s 
¾ Fatty and tough meats 
¾ Fried foods,  
¾ Spicy foods, carbonated drink 
¾ Snacking 
¾ Day sleep 
3.12 Trial Conduct: 
This study will be conducted in compliance with the protocol approved 
by the Institutional Review Board, and according to Good Clinical Practice standards. 
No deviation from the protocol will be implemented without the prior review and 
approval of the IEC except where it may be necessary to eliminate an immediate 
hazard to a research subject. In such case, the deviation will be reported to the IEC as 
soon as possible. 
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3.13 Criteria for assessment of response to therapy: 
1) Marked response : 90% relief in the presenting signs and symptoms marked 
normality pathological investigation 
2) Moderate response : 70 – 80% relief signs and symptoms, moderate normality 
of pathological investigation. 
3) Mild response : 50% relief of signs and symptoms, mild changes in 
pathological investigations. 
4) Poor response : less than 50% relief in symptoms and no significant 
improvement in laboratory parameters. 
. 
3.14 Ethical Review 
The protocol and amendments were submitted to the Govt siddha medical college, 
Institutional Ethical Committee (IEC) and got formal approval for conducting the 
study. The decision of the IEC concerning the conduct of the study was made in 
writing to the investigator. 
All subjects for this study was provided a consent form describing this study and 
provided sufficient information for subjects to make an informed decision about their 
participation in this study. This consent form was submitted with the protocol for 
review and approval by the IEC. The formal consent of a subject, using the IEC-
approved consent form, was obtained before that subject is submitted to any study 
procedure. This consent form was signed by the subject or legally acceptable 
surrogate, and the investigator-designated research professional obtaining the consent.   
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CHAPTER IV 
RESULTS AND DISCUSSION 
         Terminalia chebula, a kayakalpa drug which is compared to the mother for its 
efficacy was taken for its hypolipidemic activity. Here, various studies have been 
carried out in this study drug. 
         The study includes literary collections, Pharmacognostic study, physico and 
Phytochemicalanalysis, toxicological study, pharmacological study, and clinical 
study. The drug has been selected for the treatment of obesity in reference with 
Gunapadam mooligai vaguppu. 
         The prime action of Terminalia chebula is Rejuvenative. Botanical aspect of the 
fruit source shows the presence of tannins.Tanins act as a free radical scavenger and 
may prevent atherogenesas (Saravanan Subramanian et.al)the lateral research views 
emphasis antioxidant,antibacterial,antimutagenic properties of the drug 
1. Pharmacognostic aspect of Terminalia chebula                                                           
1.1 Macroscopic characters (Fig 1) 
The fruit is not winged. It is ovoid, faintly angled. Dry fruit is hard 
woody and it is indehiscent. Intact fruit yellowish-brown, ovoid, 20-35 mm long, 13-
25 mm wide, wrinkled and ribbed longitudinally, pericarp fibrous, 3-4 mm thick, non-
adherent to the seed, taste, astringent.  
                          Figure 1: Dried Kadukkai fruit 
 
 
 
 
 
41 
 
1.2 Microscopic characters  
In transverse sectioned view, the pericarp consists of a thin epidermal 
layer of thin cells. The cell walls of the epidermal cells are thick and have thick 
cuticle. The outer part of pericarp appears as thick dark hand which consist of thick 
peridermis zone. The peridermis includes five layers of this tabular cells. Inner to the 
periderm zone is another zone of larger rectangular cells which are arranged in more 
or less radial rows. Inner to the dark outer part of the pericarp is wide parenchymatous 
mesocarp. This inner mesocarp is a complex tissue system comprising outer thick 
layers of tangentially oriented thick walled lignified fibres. Next to the sclerotic layers 
is parenchymous part in which large and small vascular strands are scattered. Long 
irregular strands are seen spread over the mesocarp. Thus no well organized vascular 
bundles are recognized,inspite of abundance of vascular elements are present in the 
mesocarp. Diffusely distributed in the mesocarp parenchyma cells, these are 
prominent calcium oxalate druses. The druses occur in the unmodified parenchyma 
cells. The druses are solitary in the cells. The druses are 50µm thick. 
 
Figure 2 
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                                                                            Figure 3.1` 
 
 
 
 
 
 
 
 
Figure 3.2 
 
 
 
 
 
 
 
Figure 4.1 
 
 
 
 
 
 
 
 
Figure 3.2 
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Legend for the above figures 
Fig 2. T.S of- Pericarp, Entire view 
(GP Ground Parenchyma, IPC Inner Pericarp, Outer Paricarp, SC Sclerenchyma ,VS 
Vascular Strand) 
Fig.3.1. T.S of Pericarp Outer Zone Periderm 
      3.2.Outer Zone showing horizontal layers of sclerenchyma elements 
            Pe Periderm, SC Sclerenchyma 
Fig 4.1 Vascular strands in the mesocarp 
      4.2.Calcium Oxalater Crystals in the mesocarp under polarized light  
 
2. Finished form of Kadukkai Choornam (KC) 
 The KC was prepared following strictly the method mentioned in the Siddha 
text. The finished KC gave positive results to all tests for Choornam as mentioned in 
Siddha Gunapadam literature. 
 
 
Figure 5: Kadukkai Choornam 
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3. PHYSICO-CHEMICAL ANALYSIS 
Table 1: Physicochemical parameters 
S.No Parameter Mean Value 
1. Loss on Drying at 105°C 5.3 % 
2. Total Ash  3.0 % 
3. Acid insoluble Ash   0.3 % 
4. Water Soluble Extractive 53.7 % 
5. Alcohol Soluble Extractive 59.6 % 
6. Particle size Completely passes through 
sieve no.44 
7. pH 6.0 
 
 
TLC analyses 
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   After spray with visualizing agent 
S.No After Dipping in Vanillin-Sulphuric acid 
 
Rf value Colour of the spot 
 
1 0.09 Grey 
2 0.26 Blue 
3 0.34 Blue 
4 0.41 Grey 
5 0.46 Blue 
6 0.57 Blue 
7 0.60 Purple 
8 0.64 Grey 
11 0.79 Purple 
12 0.83 Purple 
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1717.8
1616.6
1448.6
1340.1
1209.4
1035.0
872.8
761.7
 
FTIR RESULTS 
 
 
 
FREQUENCY BANDS FUNCTIONAL GROUP 
3391.7 ALCOHOL/PHENOL O-H STRETCH 
1717.8 CARBOXYLIC ACID C=O STRETCH 
1616.6 AROMATIC C=C BENDING 
1448.6  
1340.1 ALKYL-METHYL 
1209.4  
1035.0 FLUORO ALKANES- ORDINARY 
872.8 AROMATIC- META DISUBSTITUTED 
BENZENE C-H 
761.7 AROMATIC C-H BENDING 
 
These bands indicate the presence of carboxylic acid, alkynes, and aromatic functional groups 
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SCANNING ELCTRON MICROSCOPE (SEM) 
 
 
The above plates indicates that all the particles are in nano level. This particle size makes. the 
choornam for better absorption. 
For drug delivery biodegradable nano particle formulations are needed as it is the intention to 
transport and release the drug in order to be effective. 
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TABLE 2: PHYTOCHEMICAL ANALYSIS OF TERMINALIA CHEBULA             
                      Qualitative Phytochemical Tests 
1. Alkaloids      Negative 
2. Triterpenes      Negative 
3. Tannin       Positive 
4. Flavonoids      Negative 
5. Steroids       Positive 
6. Glycoside       Positive 
7. Saponin       Positive 
8. Phenol       Positive 
 
Phytochemical analysis revealed that Terminalia chebula contain 
phenols,Tannin,Steroids,Saponin. 
The Tannin may act as in free radical scavenging mechanism and may prevent 
atherogenisis.Plant sterols may be interacted with the intestinal absorption of fats and 
cholesterols,it will promote the elimination of fats and cholesterol(Saravanan 
Subramanin et.al,2009) 
Phenols inhibit the lipid peroxidation(Toko Yoshioko et.al,1989) 
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TABLE 3: PRELIMINARY CHEMICAL ANALYSIS OF KADUKKAI 
CHOORNAM 
S.No. EXPERIMENT RESULT 
1 Reducing sugar - 
2 Starch - 
3 Protein - 
4 Amino acid - 
5 Albumin - 
6 Phosphate - 
7 Sulphate + 
8 Chloride + 
9 Iron + 
10 Calcium + 
11 Sodium - 
12 Potassium - 
13 Zinc - 
14 Magnesium - 
15 Alkaloids - 
16 Tannic acid + 
 
From the preliminary chemical analysis,we came to know that the trial drug have 
Tannic acid,calcium,Iron,chloride and sulphate. 
Calcium’s ability to lower cholesterol has been known for several years. People who 
live in areas with hard water are known to have a lower incidence of death and 
complications from cardiovascular disease than those who drink soft water, and it is 
believed that calcium may have something to do with this. 
It is thought to work by binding to bile acids and cholesterol in the small intestine, 
similar to the way fiber and bile acid resins work. By binding to cholesterol in the 
small intestine,  
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Cholesterol is not absorbed into the blood and is instead excreted out of the body in 
the feces.( By Jennifer Moll, About.com Guide (Updated October 08, 2008) 
Calcium can enhance the reduction of serum cholesterol in pigs that had been fed a 
high cholesterol diet, probably through alteration in the enterohepatic circulation of 
bile acids.(B.Z.De Rodes et.al,Dec 1996) 
Iron deficiency enhances cholesterol gallstone formation  
an iron-deficient diet (1) alters hepatic enzyme metabolism, which, in turn, (2) 
increases gallbladder bile cholesterol and promotes cholesterol crystal formation 
(SeahM Johnston et.al,Aug 1997) 
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4. TOXICOLOGICAL AND PHARMACOLOGICAL STUDIES 
4.1 ACUTE TOXICITY PROFILE 
Based on the results pooled from the acute toxicity study the therapeutic 
dose was fixed as 250 and 500mg/kg in this study since the drug is pharmacologically 
safe. Hyperlipidemia is associated with the heart diseases, which is the leading cause 
of death in the world. The results were discussed as Lipid profile in serum and Lipid 
profile in liver. LDL and VLDL levels were significantly increased in triton injected 
animals compared to normal control. Lipid profile in serum and liver indicates the 
increased phospholipids; triglyceride and cholesterol levels were significantly reduced 
by treatment of 250 and 500 mg kg-1 of Kadukkai Chooranam.  
 The decrease in cholesterol may indicate increased oxidation of 
mobilized fatty acids of inhibition or lipolysis. The present investigation shows that 
all triton induced rats displayed hyperlipidemia as shown by their elevated levels of 
serum and liver cholesterol, triglyceride, VLDL, LDL and also the reduction in the 
HDL level. Literature reveals that an increase in HDL cholesterol and decrease in TC, 
LDL cholesterol and TG is associated with a decrease in the risk of ischemic heart 
diseases.  
4.2 EFFICACY STUDY AGAINST HYPERLIPEMIA ON RAT 
 In general, hyperlipidemia was classified into primary and a secondary 
type clearly indicates the complexities associated with disease. Consumption of more 
fat may lead to the production of increased VLDL, resulting in the formation of 
maximum amounts of LDL which may stick to the walls of the blood vessels causing 
blockages for the normal flow of blood.  
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 Triton Wr-1339 has been widely used to block clearance of triglyceride-
rich lipoproteins to induce acute hyperlipidemia particularly, in rats it has been used 
for screening natural or chemical hypolipidemic drugs. The results shows that 
Kadukkai Chooranam produced a significant reduction in cholesterol level and also it 
reversed Triton induced hypolipidemic in rats. Similarly, Kadukkai Chooranam at a 
dose of 250 and 500mg/kg significantly lowered both plasma triglycerides and 
cholesterol levels. The reduction of total cholesterol by the Kadukkai Chooranam at 
the dose level of 250 and 500 mg kg-1 may be associated with a decrease of LDL, 
which is the ultimate aim of many hypolipidemic agents.  
 This study suggests that cholesterol-lowering activity of the Kadukkai 
Chooranam also may result from the catalytic action on LDL cholesterol for final 
elimination in the form of bile acids. Abnormalities in cellular cholesterol metabolism 
could partly be responsible for the changes in the plasma cholesterol levels in 
diabetes. Diabetes is also associated with hyperlipidemia. Serum total cholesterol and 
triglycerides have been decreased significantly in diabetic rats after Kadukkai 
Chooranam administration. These effects may be due to low activity of cholesterol 
biosynthesis enzymes or low-level lipolysis that is under the control of insulin. The 
Kadukkai Chooranam treatment also resulted in significantly reverted the level of 
LDL and HDL in serum towards the normal, which again confirms the hypolipidemic 
effect.  
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 It can be concluded that Kadukkai Chooranam 250 and 500 mg kg-1 
treatment was effective in cholesterol, TG, VLDL, LDL and HDL. The 
antihyperlipidemic activity of Kadukkai Chooranam against Triton Wr-1339 showed 
dose dependent activity when compared to control as well as Lovastatin treated 
groups. Thus, our study showed that administration of Kadukkai Chooranam of both 
250 and 500 mg kg-1 dose was effective to treat hyperlipidemia.  
Table 4: Effect of Kadukkai Chooranam on body weight of Triton-induced 
hyperlipidemic rats 
Groups Body Weight (gm.) 
Initial 1st Week 2nd Week 3rd Week 4th Week 
Normal 
control 
154.28±2.
73 
156.18±2.
35 
158.12±2.44
** 
161.22±2.92
** 
163.46±3.00
** 
Hyperlipide
mic Control 
156.24±2.
54 
156.99±2.
71 
178.22±2.60 196.84±2.48 236.13±2.75 
KC 
250mg/kg 
153.88±2.
00 
157.04±2.
36 
166.79±2.48
* 
182.40±3.22
** 
180.11±2.44
** 
KC 
500mg/kg 
156.62±2.
26 
159.00±2.
44 
166.15±2.56
* 
180.12±2.82
** 
186.18±2.52
** 
Lovastatin 
(10mg/kg/da
y) 
155.18±2.
11 
158.27±2.
68 
165.92±2.88
** 
179.37±2.46
** 
180.40±2.11
** 
Values are as mean ± SEM (n=6)  
Values are statistically significant at *P<0.05, **P<0.01, ***P<0.001  
Comparison made between Group II Vs Group I  
Group III, IV, V Vs Group II. 
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Table 5: Effect of Kadukkai Chooranam on Blood lipid profile of Triton-induced 
hyperlipidemic rats. 
Gro
up  
Treatment T.C.  T.G.  LDL HDL  VLDL  
I Normal 
Control 
70.12±2.1
5** 
66.32±2.0
1** 
50.04±1.3
7** 
35.036±8.4
0 
18.02±0.2
4** 
II Triton 
Control 
174.75±1.
452 
126.77±18
.50 
122.10±3.
34 
28.15±0.52 25.71±3.0
2 
III KC 
250mg/kg 
68.45±1.7
67** 
73.62±9.5
6** 
70.17±10.
41** 
94.51±16.4
33** 
14.30±1.2
9** 
IV KC 
500mg/kg 
73.46±2.1
07** 
56.95±1.1
52** 
55.12±6.7
45** 
50.12±8.15 11.15±0.3
2** 
V Lovastatin 
(10mg/kg/
day) 
55.58±4.7
8** 
53.15±10.
04** 
46.40±6.1
4** 
52.50±14.1
4 
10.51±2.0
4** 
Values are as mean ± SEM (n=6)  
Values are statistically significant at *P<0.05, **P<0.01, ***P<0.001  
Comparison made between Group II Vs Group I  
Group III, IV, V Vs Group II. 
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Table 6: Effect of Kadukkai Chooranam on liver lipid profile of Triton-induced 
hyperlipidemic rats. 
Gro
up  
Treatmen
t 
T.C.  T.G.  LDL HDL VLDL  
I Normal 
Control 
74.36±7.28
** 
70.62±4.28
2** 
26.182±1.1
14** 
36.158±10.
62 
14.126±0.7
75** 
II Triton 
Control 
155.41±10.
44 
178.112±1
5.212 
105.41±4.2
0 
18.040±1.2
6 
35.755±4.0
25 
III KC 
250mg/kg 
75.22±6.24
8** 
65.424±3.5
00** 
18.14±5.00
2** 
44.15±3.32
0 
12.125±0.7
12** 
IV KC 
500mg/kg 
82.7±6.952
** 
59.255±2.0
92** 
23.10±5.14
0** 
50.455±12.
024* 
12.52±0.27
4** 
V Lovastati
n 
(10mg/kg/
day) 
67.754±5.1
25** 
87.647±7.1
04** 
20.28±5.40
3** 
36.74±6.50
2 
12.11±1.45
9** 
 
Values are as mean ± SEM (n=6)  
Values are statistically significant at *P<0.05, **P<0.01, ***P<0.001  
Comparison made between Group II Vs Group I  
Group III, IV, V Vs Group II. 
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Table 7: Effect of Kadukkai Chooranam on atherogenic index and percentage 
protection of different groups. 
Groups Atherogenic Index  % Protection 
Normal control 2.38±0.16 ---- 
Hyperlipidemic 
Control 
4.65±0.22 ---- 
KC 250mg/kg 3.48±0.04 25.16 
KC 500mg/kg 3.11±0.04 33.11 
Lovastatin 
(10mg/kg/day) 
2.86±0.06 38.49 
 
Values are as mean ± SEM (n=6)  
Values are statistically significant at *P<0.05, **P<0.01, ***P<0.001  
Comparison made between Group II Vs Group I  
Group III, IV, V Vs Group II. 
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Table 8: Effect of Kadukkai Chooranam on SGOT, SGPT Total protein, Urea and 
Blood glucose levels of Triton-induced hyperlipidemic rats 
Groups SGOT(IU/L
) 
SGPT(IU/L
) 
Total 
Protein 
(gm/dl) 
Urea 
(mg/dl) 
Blood 
Glucose 
(mg/dl) 
Normal 
control 
168.18±4.70
** 
61.12±2.72*
* 
5.95±0.3
1* 
42.04±0.92
** 
84.84±1.50
** 
Hyperlipide
mic Control 
230.48±5.42 130.42±4.51 7.22±0.3
0 
26.11±0.98 93.56±1.82 
KC 
250mg/kg 
157.80±5.71
** 
64.18±2.31*
* 
6.10±0.3
0* 
34.08±2.10
* 
85.11±1.30
** 
KC 
500mg/kg 
196.48±5.48
** 
101.04±2.64
** 
6.98±0.2
8 
40.64±2.45
** 
83.10±1.14
** 
Lovastatin 
(10mg/kg/day
) 
170.14±5.60
** 
72.46±2.87*
* 
6.23±0.3
1 
36.98±2.00
** 
82.34±1.12
** 
 
Values are as mean ± SEM (n=6)  
Values are statistically significant at *P<0.05, **P<0.01, ***P<0.001  
Comparison made between Group II Vs Group I  
Group III, IV, V Vs Group II. 
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Table 9: Effect of Kadukkai Chooranam on vital organ weights of Triton-induced 
hyperlipidemic rats on day 24. 
Groups Liver(gm) Heart(gm) Kidney(gm) 
Normal control 5.45±0.28** 0.61±0.05** 0.55±0.18 
Hyperlipidemic 
Control 
7.88±0.17 1.02±0.05 0.84±0.03 
KC 250mg/kg 5.82±0.15** 0.58±0.10** 0.58±0.02 
KC 500mg/kg 6.61±0.3** 0.64±0.02** 0.64±0.03 
Lovastatin 
(10mg/kg/day) 
5.92±0.03** 0.62±0.02** 0.60±0.14 
 
Values are as mean ± SEM (n=6)  
Values are statistically significant at *P<0.05, **P<0.01, ***P<0.001  
Comparison made between Group II Vs Group I  
Group III, IV, V Vs Group II. 
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5. CLINICAL ASSESMENT 
Hyperlipidemia is typically due to a combination of environmental and genetic factors 
include obesity and dietary choices. A number of secondary causes including Diabetes 
mellitus type2, nephrotic syndrome, hypo thyroidism etc. Even though there is a lot of 
medications available for this disease, still there is a thrive for less adverse effect 
drugs. Herbal medicines are playing vital role on curing diseases without marked 
adverse effects even though on long term intake. From this plant kingdom I have 
selected this herb which proved its hypolipdemic activity preclinically. Kadukkai 
chooranam, a herbal medicine was used for this clinical trial to prove its safety and 
efficacy against hyperlipidemia. 
                               Age wise distribution 
S.No. Age in years No.of patients Percentage(%) 
1 20-30 2 4 
2 30-40 6 12 
3 40-50 24 48 
4 50-60 15 30 
5 60-70 3 6 
Total  50 100 
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0
10
20
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40
50
60
20‐30 30‐40 40‐50 50‐60 60‐70
No. of patients
Percentage(%)
INFERENCE: 
Among 50 patients, 
¾ 2 patients are between 20 to 30 yrs. 
¾ 6 patients are between 30 to 40 yrs.  
¾ 24 patients are between 40 to 50 yrs. 
¾ 15 patients are between 50 to 60 yrs 
¾ 3 patients are between 60 to 70 yrs 
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S E X  
DIS TR IBUTION
40%
60%
Male
F emale
SEX DISTRIBUTION 
S.NO SEX 
NO.OF 
PATIENTS 
PERCENTAGE 
1 MALE 20 40% 
2 FEMALE 30 60% 
Total 50 100% 
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INFERENCE: 
Among 50 patients,30 people are female and 20 people are male. 
Clinical study on kadukkai choornam in the management of hyperlipidaemia . 
S.no OP no. NAME, 
AGE/SEX 
COMPLAIN
TS 
DURATION 
OF  DAYS 
(TREATME
NT) 
   BT 
 + 
AT 
              INVESTIGATION RESULT 
              LIPID PROFILE 
TOTAL 
CHOLES
TROL 
mg/dl 
TRIGL
YCERI
DES 
Mg/dl 
HDL 
Mg/dl 
LDL 
Mg/dl 
VLDL 
mg/dl 
1 3574 MEENAKS
HI, 58/F 
Increase in 
weight, 
dyspnea 
9.7.12 to  
25.8.12 
BT 
 
222.4 128 47.2 149.2 25.6 Marked 
 
AT 190 120 50.2 110 25  
2 3584 SARASW
ATHI, 57/F 
Increase in 
weight, 
dyspnea, 
tiredness 
9.7.12 to  
24.8.12 
BT 
 
240 120 30 139.6 30.4  
AT 195 110 45 100 30 Marked 
3 5963 VATSALA
, 56/F 
Increase in 
weight,tiredn
ess 
17.7.12 to 
25.8.12 
BT 
 
190 160 30 110 45  
AT 170 100 47.4 90 35 Moderate 
4 8659 RAMALIN
GAM,60/M 
Increase in 
weight,tiredn
ess 
28.7.12 to 
5.9.12 
BT 210 140 30 140 30  
AT 180 120 50 90 25 Marked 
5 8702 DANALA
KSHMI,50/
F 
Increase in 
weight,tiredn
ess 
28.7.12 to 
4.9.12 
BT 224 128 30 152 45  
AT 190 120 45 137 25 Marked 
6 1655 MANONM
ANI,45/F 
Increase in 
weight,tiredn
ess 
9.8.12 to 
19.9.12 
BT 197.6 97 30 140 20  
AT 150 90 50 100 18 Mild 
7 1712 SELVI,45/
F 
Increase in 
weight,tiredn
ess 
9.8.12 to 
20.9.12 
BT 218 126 25 147 25.6  
AT 200 120 50 98 22.7 Marked 
8 3567 INDHIRA
NI,52/F 
Increase in 
weight,tiredn
ess 
17.8.12 to 
29.9.12 
BT 250 120 30 139 40  
AT 200 90 46 98 35 Marked 
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9 4282 DEEPA, 
24/F 
Increase in 
weight,tiredn
ess 
21.8.12 to 
30.9.12 
BT 210 130 30 140 37  
AT 190 100 45 120 30 Moderate 
10 2759 SHYMAL
A,29/F 
 
Increase in 
weight,tiredn
ess 
26.9.12 to 
30.10.12 
BT 242 120 25 150 30  
AT 190 100 45 100 25 Marked 
11  
7308 
MOHAN,5
6/M 
Increase in 
weight,tiredn
ess 
15.10.12 to 
25.11.12 
BT 270 130 30 140 40  
AT 220 120 50 90 37 Marked 
12 8858 SHANTI,4
0/F 
Increase in 
weight,tiredn
ess 
23.10.12 to 
30.11.12 
BT 250 170 27 140 38  
AT 200 150 40 120 30 Marked 
13 9207 SRIDARA
N,60/M 
Increase in 
weight,tiredn
ess 
25.10.12 to 
30.11.12 
BT 240 150 35 150 35  
AT 190 120 48 100 32 Marked 
14 9225 LATHA,35
/F 
Increase in 
weight,tiredn
ess 
25.10.12 to 
29.11.12 
 
BT 250 150 35 110 40  
AT 210 130 47 75 37 Marked 
15 981 HEMALA
THA,45/F 
 
Increase in 
weight,tiredn
ess 
3.11.12 to 
14.12.12 
BT 260 140 30 110 40  
AT 200 120 46 78 38 Marked 
16 1398 KUMAR,4
0/M 
 
Increase in 
weight,tiredn
ess 
5.11.12 to 
16.12.12 
BT 240 150 30 100 32  
AT 190 90 48 75 30 Marked 
17 1524 ARUNPUZ
HAVI,38/F 
Increase in 
weight,tiredn
ess 
6.11.12 to 
24.12.12 
 
BT 220 140 33 110 32  
AT 190 120 44 72 28 Marked 
18 1665 RADHIKA,
45/F 
 
Increase in 
weight,tiredn
ess 
6.11.12 to 
28.12.12 
BT 197 134 32 150 29  
AT 177 123 45 100 25 Marked 
19 2086 RAJAN,58/
M 
 
Increase in 
weight,tiredn
ess 
8.11.12 to 
20.12.12 
BT 270 156 32 124 33  
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AT 229 129 42 93 29 Marked 
20 2163 GEETHA,4
5/F 
Increase in 
weight,tiredn
ess 
8.11.12 to 
18.12.12 
 BT 224 144 33 120 42  
AT 187 124 47 91 32 Marked 
21 
 
2533 MAHALIN
GM,46/M 
 
Increase in 
weight,tiredn
ess 
10.11.12 to 
24.12.12 
 
BT 217 152 32 110 36  
AT 191 132 50 76 28 Marked 
22 5055 THAMIZH
SELVI,35/
F 
 
Increase in 
weight,tiredn
ess 
22.11.12 to 
29.12.12 
 
BT 256 150 34 93 40  
AT 201 120 52 78 28 Marked 
23 5836 VAISHNA
VI,35/F 
 
Increase in 
weight,tiredn
ess 
26.11.12 to 
30.12.12 
BT 240 146 36 111 35  
AT 197 126 54 98 32 Marked 
24 5832 KALYANI,
35/F 
 
 
Increase in 
weight,tiredn
ess 
26.11.12 to 
31.12.12 
BT 190 132 31 139 40  
AT 170 123 46 100 30 Marked 
25 5596 VELAMM
AL,43/F 
Increase in 
weight,tiredn
ess 
24.11.12 to 
28.12.12 
BT 240 150 35 112 43  
AT 211 110 51 89 31 Marked 
26 5579 GEETHA, 
35/F 
Increase in 
weight,tiredn
ess 
24.11.12 to 
29.11.12 
BT 228 150 38 109 36  
AT 197 110 53 89 30 Marked 
27 5577 THYAGU,
43/M 
Increase in 
weight,tiredn
ess 
24.11.12 to 
31.12.12 
BT 220 160 33 120 44  
AT 190 110 58 90 32 Marked 
28 5578 MARIYAP
PAN,44/M 
 
Increase in 
weight,tiredn
ess 
24.11.12 to 
2.1.13 
BT 234 150 28 110 37  
AT 198 110 42 90 31 Marked 
29 5612 NAGAMA
NI,57/M 
Increase in 
weight,tiredn
ess 
25.11.12to31.
12.12 
BT 217 160 32 118 32  
AT 198 120 47 97 28 Moderate 
30 5634 SARASU,4
8/F 
Increase in 
weight,tiredn
ess 
25.11.12to 
2.1.13 
BT 260 158 34 120 43  
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AT 190 110 52 90 33 Marked 
31 5645 PULAVEN
THAN,42/
M 
Increase in 
weight,tiredn
ess 
26.11.12to 
29.12.12 
BT 258 158 43 120 40  
AT 210 110 53 90 35 Marked 
32 5676 JEBA,49/F Increase in 
weight,tiredn
ess 
26.11.12to 
30.12.12 
BT 280 170 35 120 33  
AT 210 120 52 95 27 Moderate 
33 5693 ALAMEL
U,60/F 
Increase in 
weight,tiredn
ess 
27.11.12to 
31.12.12 
BT 290 158 35 110 40  
AT 200 126 55 98 30.5 Marked 
34 5732 RAMANI,4
7/F 
Increase in 
weight,tiredn
ess 
27.11.12to 
31.12.12 
BT 234 150 25 128 38  
AT 194 115 43 97 30 Marked 
35 5743 JAGA,45/F Increase in 
weight,tiredn
ess 
28.11.12to 
3.1.13 
BT 297 158 40 100 40  
AT 220 110 50 87 33 Moderate 
36 5756 NEELA,46/
F 
Increase in 
weight,tiredn
ess 
28.11.12to 
2.1.13 
BT 257 157 35 120 35  
AT 200 120 53 83 25 Marked 
37 5764 RANI,40/F Increase in 
weight,tiredn
ess 
28.11.12to 
31.12.12 
BT 233 187 43 160 34  
AT 187 112 55 104 23 Marked 
38 5832 PREETHI,5
4/F 
Increase in 
weight,tiredn
ess 
29.11.12to 
3.1.13 
BT 212 157 37 109 43  
AT 184 104 48 97 22 Marked 
39 5856 SATHIYA
45/F 
Increase in 
weight,tiredn
ess 
29.11.12to 
2.1.13 
BT 287 157 32 110 43  
AT 217 112 48 97 22 Marked 
40 5898 GAYATH
RI,56/F 
Increase in 
weight,tiredn
ess 
30.11.12to 
2.1.13 
BT 270 170 35 97 40  
AT 210 113 50 83 35 Marked 
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S.no IP no. NAME, 
AGE/SEX 
COMPLAI
NTS 
DURATIO
N OF  
DAYS 
(TREATM
ENT) 
   
BT 
 + 
AT 
              INVESTIGATION RESULT 
              LIPID PROFILE 
TOT
AL 
CHO
LEST
ROL 
mg/dl 
TRIGL
YCERI
DES 
Mg/dl 
HDL 
Mg/dl 
LDL 
Mg/dl 
VLDL 
mg/dl 
1 1184/ 
9933 
ANTHON
I,41/M 
Increase in 
weight, 
dyspnea 
2.8.12 to 
17.8.12 
BT 
 
223.4 129 47.2 149.2 25.6 Marked 
 
AT 188 119 52.2 110 25  
2 1298/ 
3358 
KANNUS
MY,52/M 
Increase in 
weight, 
dyspnea, 
tiredness 
17.8.12 to 
28.8.18 
BT 
 
243 122 32 139.6 30.4  
AT 195 113 43 102 30 Marked 
3 1369/ 
5885 
JAGADE
SAM,45/
M 
Increase in 
weight,tire
dness 
28.8.12 to 
10.9.2 
BT 
 
191 161 36 117 45.7  
AT 174 103 47.4 93 35 Moderate 
4 1381/ 
6083 
ROOPAS
EKAR,58
/M 
Increase in 
weight,tire
dness 
30.8.12 to 
11.9.12 
 
BT 213 144 32 143 30.4  
AT 184 113 52 90.6 24 Marked 
5 1414/ 
7122 
VELU,47/
M 
Increase in 
weight,tire
dness 
3.9.12 to 
29.9.12 
BT 227 123 32.7 153 43  
AT 195 118 41 137.5 27 Marked 
6 315/ 
9287 
 
RAMESH 
KUMAR,
55/M 
Increase in 
weight,tire
dness 
25.10.12 to 
9.11.12 
BT 197.6 96 30.3 140.8 22  
AT 154 87 50.1 103 18 Mild 
7 449/ 
4253 
NARAY
ANAN,40
/M 
Increase in 
weight,tire
dness 
19.11.12 to 
8.12.12 
BT 218 196 24 147.8 25.6  
AT 206 121 52 98.5 22.7 Marked 
8 586/ 
8275 
NAGAR
AJ,54/M 
Increase in 
weight,tire
dness 
6.12.12 to 
17.12.12 
BT 251 122 34.8 139 44  
AT 207 91 43 98 35 Marked 
9 480/4
811 
SHANKA
R,55/M 
Increase in 
weight,tire
dness 
21.11.12 to 
9.12.12 
BT 213 133 32 143 37  
AT 192 108 43 121 31 Moderate 
10 553/ 
6855 
PERIYA
NNA,25/
M 
 
Increase in 
weight,tire
dness 
30.11.12 to 
19.12.12 
BT 242 123 23 154 30.4  
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BMI RESULTS BEFORE AND AFTER ADMINISTRATION OF KADUKKAI 
CHOORNAM 
S.n
o 
 
OP/IP no. NAME AGE/SE
X 
BMI 
BEFORE 
TREATMEN
T 
AFTER 
TREATMEN
T 
1. 3574 MEENAKSHI 58/F 29.7 27.5 
2. 707 SARASWATH
Y 
57/F 31 29 
3. 5963 VATCHANA 56/F 29.4 28.4 
4. 8659 RAMALINGA
M 
60/M 33.2 31.2 
5. 8702 THANA 
LAKSHMI 
50/F 28.5 26.5 
6. 1655 MANOMANI 45/F 30.4 27.8 
7. 1712 SELVI 45/F 36.8 34 
8. 3567 INDIRARANI 52/F 31.6 30 
9. 4282 DEEPA 24/F 32 30.1 
10 2759 SHIYAMALA 29/F 30 28 
11 7308 MOHAN  56/M 29.1 27.2 
12 8858 SHANTI 40/F 31.1 29.4 
13 9207 SRIDHARAN 60/M 32 30.8 
14 9225 LATHA 35/F 32.6 29.7 
15 981 HEMALATHA 45/F 32.87 30.5 
16 1398 KUMAR 40/M 29.7 27.3 
17 1524 ARULKUZHA
VI 
38/F 31.1 30 
18 1665 RADHIKA  45/F 28.9 29.7 
19 2086 RAJAN 58/M 29.67 26.2 
20 2163 GEETHA 45/F 31.45 29.65 
21 2533 MAHALINGA
M 
46/M 29.43 26 
22 5055 THAMIZHSEL
VI 
30/F 30 
 
28.6 
23 5836 VAISHNAVI 35/F 29.4 27.2 
24 5832 KALYANI 35/F 30 29.1 
25 5596 VELAMMAL 43/F 32.1 29 
26 5579 GEETHA 35/F 33.2 31.9 
27 5577 THIYAGU 43/M 31 28.7 
28 5578 MARIAPPAN 44/M 29.8 27 
29 5612 NAGAMANI 57/M 31.3 29.4 
30 5634 SARASU 48/F 32 30.7 
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31 5645 PULAVENTHA
N 
42/M 29.9 27 
32 5676 JEBA 49/F 31.5 29.1 
33 5693 ALAMELU 60/F 30 27 
34 5732 RAMANI 47/F 29.9 26.8 
35 5743 JEGAN 45/F 33.4 31.8 
36 5756 NEELA 46/F 32 29.2 
37 5764 RANI 40/F 31.8 28 
38 5832 PREETHI 54/F 29 27.2 
39 5856 SATHYA 45/F 32.8 31 
40 5898 GAYATHRI 56/F 29 27.7 
41 1184/993
3 
ANTHONI 41/M 32 30 
42 1298/335
8 
KANNUSAMY 52/M 32 31.1 
43 1369/588
5 
JAGADESAN 45/M 31.4 28.6 
44 1381/608
3 
ROOPASEKAR 58/M 33 31.6 
45 1414/712
2 
VELU 47/M 29.3 25.9 
46 3115/928
7 
RAMESH 
KUMAR 
55/M 33 31 
47 449/4253 NARAYANAN 40/M 30.3 27 
48 586/8275 NAGARAJ 54/M 31.2 29 
49 281/8609 GUNA 
SEKARAN 
50/M 29 26 
50 398/3173 KANNAMANI 58/M 30 29.1 
 
Table no:10                            GRADATION RESULT 
S.NO LEVEL OF 
IMPROVEMENT 
NO.OF 
.PATIENTS 
PERCENTAGE 
(%) 
1 Marked Response 40 80 
2 Moderate Response 7 14 
3 Mild Response 2 4 
4 Poor Response 1 2 
 Total 50 100 
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INFERENCE 
Among 50 patients 
Marked response seen in 40 patients (80%) 
Moderate response seen in 7 patients(14%) 
Mild response in 2 patients (4%) 
Poor response seen in 1 patient(2%) 
Thus clinical study of kadukkai choornam on dyslipidemic patients showed a 
good result.  
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  SUMMARY 
The plant of Terminalia chebula ( Kadukkai) had  been collected  from 
Kollimallai Hills, Salem district, Tamilnadu and authenticated by experts. 
The literary review in Siddha and botanical aspects had been visibly discussed. 
The drug was subjected to step wise process of investigations like 
pharmacognostic study phytochemical, chemical and physio-chemical analysis to 
report the creditability of drug. 
From the preliminary chemical analysis,we came to know that the trial drug 
have Tannic acid,calcium,Iron,chloride and sulphate.Recent researches suggest the 
lipid lowering activity of Tannic acid,calcium,and iron. 
Phytochemical analysis revealed the presence of tannins,phenols,sterods. 
Recent studies shows phenols inhibit the lipid peroxidation and Tannin may prevent 
atherogenesis. 
Toxicity studies had its special role in placement of drug at its next level by 
establishment as safety drug. 
Hypolipiemic  activity was monitored  through Body weight,BMI and waist 
circumference along with lipid profile. The clinical study had shown good 
improvement in patients. 
As a result  of  scrutinisation of  all results the unique  Siddha medicine, 
powdered form of  of  Terminalia chebula ( Kadukkai chooranam) will be  
significantly safe and  highly effective. 
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CONCLUSION 
The trial drug  Kadukkai chooranam reveals the beneficial  activity in 
reducing lipid levels 
The model and study design demonstrates the feasibility of evaluating 
powdered form of  Terminalia chebula ( Kadukkai chooranam) in the management of 
hyperlipidemia.  
The literary reviews along with phytochemical, chemical constituent’s aids in 
justification of drug.Standardisation of drug through various physio chemical analysis 
and pharmacognostic study had emerged as a part of study for quality and 
acceptability of drug. 
The availability, collection and preparation of the drug is simple. Acute 
toxicity studies in animals had revealed the safety of the drug . 
Pharmacological study suggests that cholesterol-lowering activity of the 
Kadukkai Chooranam may result from the catalytic action on LDL cholesterol for 
final elimination in the form of bile acids. 
The clinical trial shows the possible benefits of the drug in treating 
hyperlipidemia with 80% marked response, 7% moderate response with increasing 
HDL level and decreasing LDL levels 
The study justifies the magnitude of Terminalia chebula (Kadukkai 
chooranam)  for lowering cholesterol levels and decrease the cardio vascular risks. 
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ANTIULCER ACTIVITY OF MILAGATHY CHOORNAM 
  The Siddha system is a treasure-house of secret science, gifted to the world by 
siddhars. The siddhars were pioneers in the world in the field of minerals, metals and 
medicinal herbs. 
  Siddhars have selected the drugs to treat the diseases by knowing the taste of 
the drugs and amalgamation of elements and knowing the vital thathus. In such an 
approach that is not only subsides the pathological signs and symptoms but also 
rectifies the root cause. 
 According to siddhars science, the three humours in their normal order occupy 
respectively the lower, middle and upper parts of the body and maintain their 
integrity-the vayu in the region of the pelvis and the rectum, the pitham in the region 
of the stomach and the internal viscera and the phlegam in the region of the breath, 
throat and head. The three humours maintain the upkeep of the human body through 
their coalesced function .When deranged they bring about diseases peculiar to their 
influence. When in equilibrium, freedom from diseases and when one or other of the 
humours combine in such a manner as to get deranged by aggravation diminution etc, 
disease or death may be the result. 
Vatha, pitha and kapha have multiple significance and symbolical in terms 
1. Vatha represents mind, dryness ,pain ,flatulence, lightness and also air. 
2. Pitha represents gastric juice, bile, energy, heat, inflammation, anger and 
irritation ,etc. 
3. Kapha represents feeling of cold, heaviness ,running of nose, passing of 
mucoid discharge and also the saliva 
In modern world gastro intestinal disorders are the universal problem. 
Oimmam as explained by great siddhars has clinical symptoms, closely related to 
peptic ulcer. The Gunmam is classified into eight varieties according to Yugimuni 
Vaidya Chinthamani. 
The 'Gunmam' means reduced state of metabolic and mental activities.               
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  According to siddha the cause of most ulcers lies in a mixture of vatha and 
pitha provoking factor 
It has been told by Therar as 
Å¡¾Àó¾ÁÄ¡Ð ÌýÁõ ÅÃ¡Ð 
º¢ÈôÀ¡É À¢ò¾ò¾¢ø Å¡¾ ¿¡Ê 
§º¡¢ÖÕ¾¡Ð ¿ð¼Ó¾Ã À£¨¼¯¨ÈôÀ¡¸î ¦º¡¢Â¡¨ÁìÌý ÁïÝ¨Ä... 
 
 The factors, which assumed to affect this equilibrium are environment, 
climatic conditions, diet, physical activities, and stress. 
 So proper diet, medicine and a disciplined regimen of life are advised by 
siddhars for a healthy living and to restore equilibrium of humors in diseased 
condition 
 The term ' peptic ulcer ' refers to an ulcer in the lower oesophgus,stomah or 
duodenum,in the jejunum after surgical anastamosis to the stomach or, rarely,in the 
ileum adjacent to a Meckels diverticulum.-Davidson 's principles and practice of 
medicine-ll81 edition. 2010. 
 Peptic ulcer occurs in that part of gastrointestinal tract which is exposed to 
gastric acid and pepsin,i.e.the stomach and duodenum.lt results probably due to an 
imbalance between the aggressive(acid,pepsin and bile) and the defensive(gastric 
mucus and bicarbonate secretion, prostaglandins, nitric oxide,innate resistance of the 
mucosal cells) factors Medical pharmacology, KD Tripathy 6th edition. 2010 
 Hypersecretion of gastric acid is a pathological condition,which occurs due to 
uncontrolled secretion of hydrochloric acid from the parietal cells ofthe gastric 
mucosa through the proton pumping H+K+ATPase. Even the normal rate of acid 
secretion may cause ulceration in the breached mucosa when some gastro protective 
factors are lost. 
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 Dieteric indiscretion such as overeating, taking of heavy meals or highly 
spiced foods, coffee, alcohol and smoking are the main factors contributing to this 
condition. Other causes are the ingestion of certain drugs, food poisoning, certain 
infections, gout, emotional disturbances, stress, and nervous tension 
 The modern approach to control gastric ulceration is to inhibit gastric acid 
secretion, to promote gastroprotection, block apoptosis and stimulate epithelial cell 
proliferation for effective healing. Most ofthe antisecretory drugs such as proton 
pumpinhibitors (omeprozole lansoprazole, etc.) and histamine H2-receptor blocker 
(ranitidine,famotidine, etc.) are extensively used to control increased acid secretion 
and acid related disorders . But there are reports of adverse effects and relapse in the 
long run. 
  On the contrary most of the  siddha drugs reduces the offensive factors and 
are proved to be safe clinically effective, having better patient tolerance,relatively less 
expensive and globally competitive. 
 In siddha the treatment should be commenced as early as possible after 
evaluating the course and cause ofthe disease. Treatment is classified into three 
categories: devamaruthuvum (Divine method); manuda maruthuvwn (rational 
method); and asura mamihuvum (surgical method). In Divine method, medicines like 
parpam,chendoomm, guru,kuligai made of mercury, sulfur and pashanams are used. 
In the rational method, medicines made of herbs like choornam,kudineer or vadagam 
are used. In surgical method, incision, excision, heat application, blood letting, or 
leech application are used. 
  Choornas are fine dry powder of drugs. They are often easier to make for 
compounds that consist of many ingredients. Powders usually have quick action. They 
work mainly on the gastro intestinal tract and rasa thatu or plasma.Milagathi 
chooraam ,a herbo mineral formula which consist of chukku(Zingiber officinale, 
milagu(Piper nigrum), thippili(Piper longum), karunjeeragam(Nigella. sativa), 
omam(Cummum cyminum), perungayam(Ferula. asafoetida), Kadukkai(Terminalia 
chebula) and indhuppu(Sodium chloridelmpura). In that formula indhuppu is a 
mineral.  
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 In siddha system,minerals are divided into three major divisions.  They are 
pashanam, Karasaram and uparasam. Karasaram (uppu) are totally 25, out of this 15 
are synthetic and 10 are natural salts.Indhuppu is one among the synthetic karasaram. 
Karasarams are of great medicinal value. Other herbals in this madicine are well 
known for their action on gastro intestinal tract. Every ingredient in this medicine 
(milagathi choornam) has the power to cure gunmom which has been clearly 
mentioned with their general characterestics as a script in Agathiar guna vagadam .So 
the author has decided to see the efficacy of the milagathi choornam in the clinical 
study of antiulcer activity 
             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 81 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 82 
 
CHAPTER  I 
AIM & OBJECTIVE 
1. Aim : 
 To validate the safety and efficacy of Milagathi Choornam in the management 
of Peptic ulcer   
2. Objectives: 
               In this dissertation work, the “MILAGATHI  CHOORANAM’ is analyzed 
in 
       the following aspects: 
• Standardization of Milagathi choornam including pharmacognostic 
characterization of raw drug and purity analyses 
• Safety profile for the test drug in rodents 
• Pharmacological study to evaluate the anti-ulcer activity in rat 
• Open clinical study to assess the safety and efficacy of the drug on Peptic 
ulcer patients. 
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CHAPTER II    
REVIEW OF LITERATURE 
 Indhuppu 
Sodium chloride impura 
Vernacular names 
English - Rock Salt;Sea salt:Bay salt;Sodium chlorate 
Tamil  - Indu-uppu 
Hindi - Sedhalon;Sendhalon 
Sans - Saindhava 
Arab  - Mil-he-tabazard 
Ger - Natrium chloricum 
Tel - Saindhalavanam 
Mal - Intu-uppu 
 Source 
            Found in nature in extensive bed mostly associated with clay and calcium 
sulphate. To obtain a, holes are dug into these rocks which soon become filled up with 
salt water; the water is evaporated and the salt is left ready for use. 
Character 
          It is found in small white crystalline grains or transparent cubes. It is brownish 
white externally and white internally. It has pure saline taste and burns with a yellow 
flame. 
Action 
         In small dozes it is highly carminative, stomachic and digestive.It promotes the 
appetite and assists digestion and assimilation. In large doses(1-2drachms)it is 
cathartic;in still larger doses(4-8drachms)it is emetic. 
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Uses 
       It is given in dyspepsia and abdominal disorders.  
 A compound powder called Vadavanal churna containing rock salt, long 
pepper, pipli, cubeb, chitrak,ginger and myrobalans in equal parts, mixed and made 
into a powder used in anorexia, flatulence and biliousness. 
Dose-5 to 15 grains two or three times a day with water. 
PREPARATIONS 
Thengaisharam 
 Take a coconut fruit full of water make hole in it and fill the coconut with rock 
salt and dissolve it in it water. Then close the opening, cover the nut with a layer of 
clay and roast in a pit of fire. The salt thus roasted is given with the addition of long 
pepper. 
Dose: Quarter tola  
Uses: It is valuable in the form of dyspepsia which is attended with pain two or three 
hours after meals. 
  A powder made of rock salt 10 grains kaladana scale 1 drachm and dry ginger 
10 grains is a good laxative in a single dose.  
  As a digestive a compound powder made of rock salt, chebulic myrobalan, 
emblic myrobaln and long pepper in equal part is recommended in dose 10 grains 
twice a day. 
 A powder containing pancha lavana 5 parts impure oxide of iron 5 parts and 
emblic myrobaln 4 parts is useful in doses of 10 grains in dyspepsia, congested liver 
etc. 
(Ref:Dr.K.M.Nadkarni&s Indian material medica Volume-2 page no:108) 
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General character-indhuppu 
«ð¼ÌýÁ Áó¾õ «º¢÷ì¸ÃïÝ÷ º£¾À¢ò¾ó 
Ðð¼¨ÅÂõ ¿¡ÊôÒñ §¼¡¼í¸û- ¦¸ð¼ÁÄì 
¸ðÎÅ¢¼ Å¢ó¨¾Âì ¸¡Á¢Ä§¿¡ö Åý¸ÃôÀ¡ý 
Å¢ðÎÅ¢¼ Å¢óÐô¨À Å¢ý 
    Induppu is specially given for eight types of ulcer. kabha diseases, constipation, 
eczema are cured by Indhuppu  
Preparations that contain Indhuppu 
Indhuppu choornam 
Indhuppu - 1part 
Cuminum cyminum - 1part 
Trachyspermum ammi - 4parts 
Piper longum - 4parts 
Zingiber officinale - 16parts 
Terminalia chebula - 32parts 
All the above powders are mixed well 
Dose : 12gms 
Uses : Indigestion,vomiting,ascites. 
2)  PANCHALAVANA CHUNNAM 
Savukkaram - 1part 
Valayulluppu - 1/4part 
Indhuppu - 1/4part 
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Vengaram - 1/4part 
Kariuppu - 1/4part 
All the above are rubbed rogether in a kalvam with amuri made into villai.then 
enclosed in agal and subjected to putam with 5varratties 
Dose : 650mg 
Uses : abdominal pain, ulcer 
CHUKKU 
Botanical name: Zingiber officinale 
Family : Zingiberaceae 
VERNACULAR NAMES 
English : Dried ginger 
Hind : Sonth 
Tel : Sonti 
Mal : chukku 
 
Dried Ginger is Called Chukku 
Part used : Rhizome 
Actions : Stimulant, Stomachic, Carminative 
ÍìÌì ¸üÀõ 
Íì¸¢¨Éô ¦À¡Ê ¦ºöÐ ÝÃ½Á¡ì¸¢ 
Â¢ì¸¢Ãò¾¢ÖñÊ¼ÅÂ¢ü ¦È¡¢×§À¡í 
ÌÊ¿£÷ ¦ºö¾¨¾ì ÌÊ¿¢¾ ¿ý¨ÁÂ¡õ  (§¾Ãý ¦ÅñÀ¡) 
 Dried ginger powder is mixed with sugarcane juice.when it is given in the morning. It 
relieves burning stomach.Dicoction of the dried ginger is always good for health. 
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Chemical constituents 
Aromatic volatile oil, The volatile oil contains camphene and 
phallandrene, Zingiberine, Cineol, Berneol, Gingerin, Gingerol, Resin, Starch 
Uses 
 Dried ginger is aromatic, and carminative, produces a sensation of warmth at 
the epigastrium and expels flatus.  As a carminative it is given in colic The dry 
rhizome powdered and made into a paste with warm water is used as a cataplasm or 
fomentation to the forehead in headaches, neuralgia, colic and toothache; also given in 
dyspepsia, loss of appetite, to correct the flatulence in colic,diarrhea etc. 
 
Research highlights 
 Anti ulcer principle in ginger. An anti ulcer compound 6 gingesulphonic  acid 
and three mono acyldigalactosyglycerols, Gingeglycolipids A,B, and C are isolated 
from dried  rhizome of  zingiber officinale which was cultivated  in Taiwan . 
 The phenolic constituents of the alcohol soluble fraction in responsible for its 
anti oxidant effect. (YoshikanM et.al,) 
MILAGU 
Botanical name: Piper nigrum 
Family                 :Piperaeae 
VERNACULAR NAMES 
Eng  : Black pepper 
Hind: Kall-mirch 
Mal : Kurumulaku 
Pers: Flifliaisiah 
Kan: Menasu 
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Part used: Seeds 
Actions: 
Acrid, Carminative, Antiperiodic, Rubefacient, Stimulant, Resolvent, Antivatha, 
Antidote 
General character of Piper nigrum 
º£¾ÍÃõ À¡ñÎ º¢§ÄòÁí ÌýÁõ 
Å¡¾õ «Õº¢ À¢ò¾õ Á¡ãÄõ- µÐºýÉ¢ 
Â¡ºÁŠÁÀŠ Á¡Ãõ «¼ý§Á¸õ ¸¡ºÁ¢¨Å 
¿¡ºí ¸È¢Á¢Ç¸¢É¡ø 
Pepper cures fever, anemia, kabam, dysentry, ulcer, vatham 
 
Uses 
          Black pepper as culinary spice and condiment is well known throughout the 
world. Black pepper growing in Malabar cost is the best, and as stimulant and 
carminative is prescribed in choleras, dyspepsia, flatulence, diarrohea and various 
gastric ailments. 
Black pepper is useful for dyspepsia and flatulence when taken ten to fifteen grains. 
(Ref:Dr.K.M.Nadkarni & Indian material medica) 
CHEMICAL CONSTITUENTS 
          Black pepper contains volatile oil and piperine, piperidine, piperettine, and a 
few other minor alkaloids (piperyline, piperolein A, piperolein B, piperanine, 
etc.).Piperine and piperanine are the known pungent principles. 
 Chavicine and many other amide alkaloids have recently been isolated, for 
example, pipwaqarine, piptigrine, pipnoohine, pipyahyine, pellitorine, guineensine, 
pipercide, retrofractamide A, dipiperamides D and E  and others.  
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 Black pepper is also reported to contain flavonol glycosides (especially those 
of kaempferol, rhamnetin, and quercetin) in considerable concentration, as well as 
sterols (stigmastane-3, 6-dione and stigmast-4-ene-3,6-dione) and polysaccharides.  
Pepper oil contains a complex mixture of monoterpenes (70–80%), sesquiterpenes 
(20–30%), and small amounts of oxygenated compounds, with no pungent principles 
present. Concentration and composition vary, depending on sources. Major 
monoterpenes include α-thujene, α-pinene, camphene, sabinene, β-pinene, myrcene, 
3-carene, limonene, and β-phellandrene. Sesquiterpenes include β-caryophyllene 
(major component), β-bisabolene, β-farnesene, ar-curcumene, humulene, β-selinene, 
α-selinene, β-elemene; α-cubebene, α-copaene, and sesquisabinene. Oxygenated 
components include linalool, l-terpinen-4-ol, myristicin, nerolidol, safrole, β-pinone, 
and N-formypiperidine, among others.  
Thippili 
Botanical name : Piper longum 
Family  : Piperaceae 
Vernacular Names 
Eng : Long pepper 
Tel : Pippillu 
Mal : Thippili 
Kan : Hippili 
Part used : Fruit 
Action : Stimulant , Carminative 
General character of Piper longum 
þÕÁø ÌýÁõ þ¨ÃôÒ ¸ÂôÀ¢½¢ 
    ®¨Ç ÀñÎ ºóÂ¡ºõ «§Ã¡º¸õ 
¦À¡ÕÁø °¨¾ º¢ÃôÀ¢½¢ ã÷î¨º§¿¡ö 
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    â¡¢ìÌïºÄ §¾¡¼õ À£Ä¢¸Óõ 
ÅÕÁÄô ¦ÀÕì §¸¡Î Á§¸¡¾Ãõ 
    Å¡¾õ ¬¾¢Óò§¾¡¼ï ÍÃíÌÇ¢÷ 
¦ÀÕÁ¡¨ÄôÒ¡¢ §Á¸ô À¢¼¸Óõ 
    §ÀÕó ¾¢ôÀ¢Ä¢ô §ÀÃíÌ¨Ãì¸§Å 
Preparation and uses 
  A common use of Piper longum in Indian medicine is for the prevention of 
recurrent attack of bronchhial asthma recurrent infection of throat and for flatulence 
and dyspepsia 
(Ref: Indian herbal remedies) Active principles and pharmacology 
 Fruit gave alkaloids  
N – isobutyldeca – trans 2,  trans 4 diananmide 
Essential oil from fruit contain n-hexadecane,n-heptadecane,n-nonadecane 
p-cymene,L-tyrosene,L-cysteine hydrochloride 
(Ref: Indian herbal remedies C.P.Khare) 
Omum 
Botanical name : Trachyspermum ammi 
Family : Apiaceae 
 
Vernacular Names 
Eng : Bishop’s weed 
Hin : Ajowan, Ajwan 
Tel : Vaamu 
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Tam : Omum, Asampadam , Amam 
Mal : Omum, Ayamodakam 
 
Part used : Seed 
Actions : Anthelmintic, Antiseptic, Stomachic, Antispasmodic, Carminative, 
Sialogouge, Stimulant, Antiseptic, Tonic 
CHEMICAL CONSTITUENT 
1. Ajowan fruits contain 2-4% of volatile oil about 21% of fat,17% proteins and 
25% carbohydrate, trace of tannin, glycoside and steroidal substances have 
been reported 
2. Volatile oil mainly contains Thymol (35-60%), P-Cymene 50-55%, Terpinene 
30-35%, Pinene, Dipenetenes etc, are other constituents of the oil. The flavor 
and taste of drug is due to thymol and volatile oil 
PROPERTIES AND USES 
1. It is administered in flatulence, atonic,dyspepsia ,diarrhea and often 
recommended for cholera 
2. It has been shown to possess antibiotic activity against salmonella typhi 
Micrococcus pyogenes variant aureus and Escherichia coli 
3. Ajowan is used as a house hold remedy for indigestion 
4. Oma water which is commonly used in India as a carminative and is useful in 
flatulence and griping, especially in children. The water left over after the 
essential oil and thymol have been removed from the steam distillate  
Reference - Indigenous Drugs of India – Chopra R.N      
Karunjchirakam: 
Botonical name : Nigella sativa linn 
Family : Ranunculaceae 
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Vernacular Names 
Eng : Black cumin 
Hind : Kulanji 
Tel : Nalla – jilakarra 
Mal : Karinchirakam 
Kan : Karl-jirige 
Part Used: Seeds 
Action :        Carminative, Diuretic, Emmenagogue,  Galactogogue,  Anthelmintic, 
Stomachic, Parasiticide, Emollient 
Chemical Constituents 
 Black cumin seeds contain a bitter principle nigellin, tannins, reducing sugar 
mostly gluose saponins and Arabic acids and other alcohol-soluble organic acid. The 
free amino acid present in dormant seed are cystine, lysine, aspartic acid, glutamic 
acid, alanine, tryptophan, valine and leucine;  
(Indian herbal remedies K.P.Khare) 
Kadukkai 
Botanical name: Terminalia chebula 
Vernacular names 
English : Chebulic Myrobalan  
Tamil : Kadukkai  
Sanskrit : Haritaki, Priya, Sudha   
Hindhi : Pile Hara  
Pers : Haleelai Siah  
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Kan : Anile-Kayl  
Tel : Chitti karakkaya 
Mal : Katuukkaipinja  
        Kadukkukkai embodies all the taste except salt. According siddha it is classified 
into seven types. They are  
Vijaya : looks just a squash and can be used in any case. 
Rohini : is round in shape and more effective for healing. 
Putana : is small in size with big hard seeds, and is useful for external plastering.  
Amrita : is fleshier, and good for body purification.  
Abhaya : has five lobes, and is more effective for ophthalmic use (external). 
Jivanti : is yellow in color and good for all cases. 
Chetaki : has three lobes, is good to use in the form of powder, and is more 
laxative than the others. Chetaki comes in two varieties 
Preparation and Uses 
Kadukkai vadagam: 
Dose : 1or 2 
Uses : vomiting, peptic ulcer, asthma,piles 
Pavana kadukkai 
Uses : cough, peptic ulcer, asthma, vomiting, piles 
Active Principles and Pharmacology 
 Fruit contain chebulinic acid,tannic acid and chebulin Oil from kernels yielded 
palmitic, searic,oleic, linoleic, arachidic and behenic acids. Antioxidant constituents 
of the plant, phloroglucinol and pyrogallol, have been isolated along with ferulic, 
vanillic, p-coumaric and caffeic acids. 
 Ether extract showed higher antioxidant activity than BHA and BHT.Acid 
esters present in phenolic fraction of extract were found more effective. 
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 A new ellagitannin-terchebulin-has been isolated from fruits along with 
punicalagin and terflavin A and its structure has been elucidated.Terflavins B,C and 
D,punicalagin and punicalin have been isolated from leaves. 
 Gallic,triacontanoic and palmitic acids,beta-sitosterol, doucosterol,riehyl ester 
of gallic acid from fuits have been isolated.A new triterpene-chebupentol-has been 
isolated from fruits;arjungenin,terminoic acid arjunolic acid have been isolated.  
 The oil in the kernel increased the motility of the gastrointestinal tract of the 
mouse. The action was comparable with castor oil.The oil itself is non irritant,but 
releases an irritant principle when incubated with lipase  
(Indian herbal remedies) c.p.khare 2004  
 96 
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Disease review-Modern aspect 
Peptic ulcer disease 
 The term ´Peptic ulcer ´ refers to an ulcer in the lower oesophagus, stomach or 
duodenum in the jejunum after surgical anastomosis to the stomach or , rarely , in the 
ileum adjacent to Meckel’s diverticulum. 
 It results probably due to an imbalance between the aggressive (acid, 
pepsin,bile and H.pylori) and the defensive( gastric mucus and bicarbonate secretion, 
prostaglandins, nitric oxide , innate resistance of the mucosal cells)  factors. 
Etiology of peptic ulcer: 
Hereditary: 
 Genetic & blood group: run in families espcially blood group (3: 1) of other 
blood groups, ABO gene may modify the size of parietal cell mass 
Dietary habits:  
 Spicy foods, Vitamin A deficiency 
Non Steriodal Anti Inflammatory Drugs: 
 Accounts to 3 % of ulcers 
Smoking and alcohol: 
 Due to inhibition of pancreatic bicarbonate by nicotine with increased risk of 
complication. 
Helicobacterium Pylori:  
 Submucous spirochetal bacteria split urea to ammonia. The high alkalinity of 
ammonia stimulate G cells to secrete gastrin   which reduces the resistance of gastric 
mucosa  
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Psycosomatic factors:  
 Stress and anxiety due to Burns, CNS trauma, Surgery and severe medical 
illness 
Hormonal factors: 
 Hyperparathyroidism increase in Ca increase HCl,Hormonal over secretion by  
islets  of pancreas  to secrete gastrin in excess. (Zollinger-Ellison Syndrome). 
Pathology: 
Incidence : male more than female. 
Duodenal : Gastric 4: 1 
Site  :  Lesser curvature of stomach, First part of  
                                                    the duodenum  
Size  :   Less than 1 inch  
Shape :   Usually oval or rounded. 
Clinical Features: 
Recurrent abdominal pain which has 3 notable characteristic  
1) Pain in epigastrium 
2) Pain starts within three hours of eating food and it may be described as 
burning, aching pressure, fullness or as a sensation of hunger 
3) Pain may be more prominent at night, the pain is usually relieved by food, 
antacids, or even by vomiting. 
 
Physical examination  
Tenderness in the epigastrium or to the right of the midline. Ulcer patients are 
able to localize the pain and this feature helps to distinguish them from cases 
of functional dyspepsia.  
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Differential diagnosis 
Epigastric pain is the common symptom in several alimentary disorders such as 
1. Gastric carcinoma 
2. Pancreatic carcinoma 
3. Pancreatitis 
4. Biliary tract disease  
5. Peptic ulceration of the esophagus 
6. Tiuodentitis  
7. Ancylostomiasis 
 
Complications 
1. Hematemesis 
2. Melena 
3. Pyloric obstruction 
4. Perforation 
5. Pancreatitis  
Investigations   of peptic ulcer: 
• CBC 
• Double  contrast barium meal  examination 
• Upper  GI  endoscopy 
• H. Pylori 
       Serologic antibody test for HP,   
• Fecal antigen test tests for active HP 
• Urea breath test tests for active HP 
Life style modifications: 
1. To avoid smoking, alcohol, betal nut chewing  ,Coffee, Tobacco 
2. Timely intake of food, avoiding oily and fried foods 
3. Smoking   and alcohol cessation 
4. Stress reduction 
5. Discontinue NSAIDs 
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CHAPTER III 
MATERIALS AND METHODS 
 
1. STANDARDIZATION OF MILAGATHI CHOORNAM 
1.1  Materials: 
 Milagathichooranam has been selected from the classical siddha literature “  
Maruthuva asiriyam”(page.no.66),Publisher.T.Mohan Raj.Ingredients of the test 
drug are as follows: 
1. Sodium chloride impura 
2. Zingiber officinale 
3. Piper nigrum 
4. Piper longum 
5. Trachyspermum ammi 
6. Ferula asafetida 
7. Nigella sativa 
8. Terminalia chebula 
 1.2 Collection of the drugs: 
Trachyspermum ammi: 
 250 gram of the raw drug was collected from the Tampcol raw drug store at 
Chennai. The adulteration particles were cleaned well.  
Sodium chloride impura: 
 250 gram of the raw drug was collected from the Tampcol raw drug store at 
Chennai. The adulteration particles were cleaned well. 
Piper longum: 
 250 gram of the raw drug was collected from the Tampcol raw drug store at 
Chennai. The adulteration particles were cleaned well. 
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Terminalia chebula: 
 500 gram of the raw drug  were collected from the Tampcol raw drug store at 
Chennai. The adulteration particles were cleaned well. 
Ferula asafetida 
:500 gram of the raw drug  were collected from the Tampcol raw drug store at 
Chennai. The adulteration particles were cleaned well. 
Nigella sativa: 
 500 gram of the raw drug was collected from the Tampcol raw drug store at 
Chennai. 
Zingiber officinale 
       500 gram of the raw drug was collected from the Tampcol raw drug store at 
Chennai. 
Piper longum 
      500 gram of the raw drug was collected from the Tampcol raw drug store at 
Chennai. 
All materials were identified and confirmed by the Head of the Gunapadam 
department, GSMC, Chennai. 
1.3  Purification of the raw materials: 
1.  Sodium chloride impura:  Soaked in vinegar for 3 days and then dried under the 
sun. 
2. Piper longum :  soaked in lemon juice and then dried under the sun 
3. Zingiber officinale:  skin is peeled off 
4. Piper longum: Soaked in vinegar and then dried under the sun. 
5. Trachyspermum ammi : soaked in lime stone water for 3 hours and then fried  
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6. Ferula asafoetida : Asafoetida is fried 
7. Terminalia chebula: 
  Seeds were removed, and rinds part only used. 
8. Nigella sativa: Fried 
1.4 Preparation of Milagathi chooranam: 
After purification process, each material should be complete dried and was 
powdered separately by grinding method. Those powder was sieved by white cloth 
(Vasthirakayam). 
Preservation: 
               The purified Chooranam was stored in a clean, air tight glass container. 
Life span : 
                3 Months. 
Administration of the drug: 
 Form of the medicine  : Chooranam 
Route of Administration : Enteral 
Dose  :  500 mg 
Anubanam (Vehicle)        : With food 
Time of Administration : Two times a day with food 
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INGREDIENTS OF MILAGATHI  CHOORNAM 
                             
  Fig1     Karunjeeragam             Fig2    Kadukkai                Fig3    Thippili 
 
           Fig4 Chukku               Fig5 Induppu   Fig6 Omam 
 
                                     
          
                  Fig7  Perungayam           Fig8   Milagu 
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1.5 Physico chemical analyses 
1.5(a) Physico chemical parameters  
Determination of Total Ash 
  3 g of the powder was incinerated in a silica dish at a temperature not 
exceeding 450º until free from carbon, cool and weigh. The percentage of ash was 
calculated with reference to the air-dried drug. 
Determination of Acid Insoluble Ash 
 The obtained ash was boiled for 5 minutes with 25 ml of dilute hydrochloric 
acid and insoluble matter was collected in ashless filter paper. Then, it was washed 
with hot water and ignited to constant weight. The percentage of acid-insoluble ash 
was calculated with reference to the air dried drug. 
Determination of Alcohol Soluble Extractive 
 5 g of powder was mixed with 100 ml of Ethanol of the specified strength in a 
closed flask and kept alone for twenty-four hours.  Filtered rapidly with taking 
precautions against loss of solvent.  25 ml of the filtrate was evaporated to dryness in 
a tared flat bottomed shallow dish, and dried at 105º, to constant weight and weighed. 
The percentage of alcohol-soluble extractive was calculated with reference to the air-
dried drug. 
Determination of Water Soluble Extractive 
 5 g of powder was mixed with 100 ml of chloroform water of the specified 
strength in a closed flask and kept alone for twenty-four hours.  Filtered rapidly with 
taking precautions against loss of solvent.  25 ml of the filtrate was evaporated to 
dryness in a tared flat bottomed shallow dish, and dried at 105º, to constant weight 
and weighed. The percentage of water-soluble extractive was calculated with 
reference to the air-dried drug. 
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Determination of Moisture Content (Loss on Drying) 
 10 g of drug was taken in the tared evaporating dish and dried at 105º for 5 
hours, and weighed. (Continue the drying and weighing at one hour interval until 
difference between two successive weighing corresponds to not more than 0.25 per 
cent. Constant weight is reached when two consecutive weighing after drying for 30 
minutes and cooling for 30 minutes in a desiccator, show not more than 0.01 g 
difference). 
Potential of Hydrogen (pH) 
 The pH scale is logarithmic and runs from 0.0 to 14.0 with 7.0 being neutral. 
Readings less than 7.0 indicate acidic solutions, while higher readings indicate 
alkaline or base solutions.  
1.4(b) THIN LAYER CHROMATOGRAPHY 
Solvent system 
Toluene : Ethyl acetate: Acetic acid  (5 : 5 : 0.5). 
TLC plate 
  Aluminium plate precoated with silica gel 60F254 of 0.2 mm thickness 
(Merck). 
Developing chamber 
 Camag’s twin trough chamber. 
Visualizing reagent 
 Vanillin-sulphuric acid reagent. 
Extract Preparation 
4 g of the chooranam was soaked overnight in chloroform. Boiled on a water 
bath for 10 mins, filtered and concentrated to 10 ml.  
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Procedure 
 The extract was applied on the TLC using capillary and developed in the 
solvent system.  The developed TLC plate was air dried and photograph was taken in 
white light. Then dipped in vanillin-sulphuric acid reagent, heated in an oven at 
105°C until the development of coloured spots and photograph taken. 
1.4 (c). Qualitative Phytochemical Analysis: 
S.No EXPERIMENT OBSERVATION INFERENCE 
1. Test for Alkaloids: Alkaloids 
are identified by precipitate 
method 
Dragendroff’s reagent: 
An aqueous plant extract 
of 2 ml is mixed with 2 ml 
of Dragendroff’s reagent. 
 
Prsence of reddish 
brown precipitate 
 
Presence of 
alkaloids 
2. Test for Triterpenoids 
(Noller’s Test) 
To few mg of extract, add tin 
and thionyl chloride and heat 
in water bath. 
       
 Absence of purple 
colour 
 
 
Absence of  
Triterpenes 
3. Test for Tannins:A plant 
sample dried powder 0.5 gm is 
boiled in 20 ml of water and 
filtered. The filterate 2 ml is 
taken and 3-5 drops of Fecl2  
(0.1%) is slowly added to it. 
 
Forms a brownish-
green or bluish- black 
colour. 
 
Presence of 
Tannins 
4. Test for Flavonoids: An 
aqueous filterate of plant 
 
Presence of  Yellow 
 
Presence of 
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sample is mixed with 5 ml of 
dilute Ammonium solution and 
few drops of concentrated 
H2SO4  is slowly added through 
the sides of the test tube. 
colour formed flavonoids 
6. Test for Glycosides:An 
aqueous plant extract of 2 ml is 
added with 1 ml of 
concentrated Hcl and boiled in 
a water bath for about 2 hours. 
The filtrate is separated and 3 
ml of chloroform is added, 
then 10% of 1ml Ammonium 
solution is added.  
Absence of pink colour 
formation 
Absence of 
glycosides 
7. Test for Saponin: A 
powdered 2 gm of plant 
sample is boiled with 20 ml of 
distilled water, then filtered, 
the filterate is added with fresh 
5 ml of distilled water and 
shaken vigorously. 
A permenant or 
persistant froth is 
formed.The froth is 
turned in to emulsion 
by adding three drops 
of olive oil. 
Presence  of 
saponin 
8. Test for Phenolic 
compounds: 
  About 2 ml of aqueous plant 
extract is mixed with 2 ml of 
Fecl3 solution.  
Presence of deep bluish 
green colour  
Presence of 
phenolic 
compounds 
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Methodology for Chemical Analysis 
Preparation of Extract : 
Add 5 gm of the sample to 50ml of distilled water. Boil the solution for 20 minutes, 
cool and then filter. Use the Extract for the following tests. 
S.No Experiment Observation Inference 
1. Test for reducing Sugar : 
To 5ml of Benedicts qualitative 
reagent, add 10 drops of extract, 
then boil for two minutes 
Green / Yellow / 
Red PPT 
Presence of 
Reducing Sugar 
2. Test for Starch : 
To 5 ml of extract add 2ml of 
acetic acid and then add few drops 
of N/50 Iodine Solution. 
Blue Colour Presence of 
Starch 
3. Test for Proteins : 
To 2 ml of extract, add 2ml of 5% 
Sodium Hydroxide mix and add 2 
drops of Copper Sulphate Solution. 
Violet or Purple 
Colour 
Presence of 
Proteins 
4. Test for Amino Acid : 
Place  2 drops of extract on a filter 
paper and allow to dry well. Then 
spray 1% ninhydrin over the same 
and allow to dry. 
Violet Colour Presence of 
Amino Acid 
5. Test for Albumin : 
To 2 ml of extract, add 2ml of 
Esboch’s reagent. 
Yellow PPT Presence of 
Albumin 
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6. Test for Phosphate : 
To 2ml of extract, add 2ml of 
ammonium Molybdate solution 
and 2ml of concentrated Nitric 
Acid. 
Yellow PPT Presence of 
Phosphate 
7. Test for Sulphate : 
To 2 ml of extract add 2ml of 4% 
ammonium oxalate solution. 
White PPT Presence of 
Sulphate 
8. Test for Chloride :  
Add 2ml of extract to dilute nitric 
acid till the effervescence ceases. 
Then add 2 ml of Silver Nitrate 
Solution. 
Cloudy White PPT Presence of 
Chloride 
9. Test for Iron : 
To 2ml of extract, add 2ml of 
ammonium thio cynate solution 
and add 2ml of concentrated Nitric 
Acid. 
Red Colour Presence of Iron 
10. Test for Calcium : 
To 2 ml of extract, add 2 ml of 4% 
ammonium Oxalate Solution. 
White PPT Presence of 
Calcium 
11. Test for Sodium : 
Make a paste with 2 pinches of the 
sample with Hcl and Introduce it 
into the blue flame.  
Yellow Flame Presence of 
Sodium 
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12. Test for Potassium : 
Add a pinch of the sample to 2 ml 
of Sodium Nitrate Solution. Then 
add 2ml of Cobal Nitrate in 20% 
acetic acid. 
Yellow PPT Presence of 
Potassium 
13. Test for Zinc : 
To 2ml of extract, add few drops of 
Sodium Hydroxide. 
White PPT Presence of Zinc 
14. Test for Magnesium : 
To 2ml of extract, add few drops of 
Sodium Hydroxide Solution 
White PPT Presence of 
Magnesium 
15. Test for Alkaloids : 
a. To 2ml of extract, add 2ml 
of Potassium Iodide 
Solution 
b. To 2ml of extract add 2ml 
of Picric Acid. 
c. To 2 ml of extract add 2ml 
of Phosphotunqstic Acid. 
 
Red Colour 
 
 
Yellow Colour 
 
White PPT 
 
Presence of 
Alkaloids 
 
Presence of 
Alkaloids 
Presence of 
Alkaloids 
16. Test for Tannic Acid : 
To 2ml of extract add 2 ml of 
Ferric Chloride Solution 
Black PPT Presence of 
Tannic Acid 
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1.4 (d) FOURIER TRANSFORM INFRARED SPECTROSCOPY (FTIR): 
INSTRUMENT DETAILS: 
Model : Spectrum one: FT-IR Spectrometer  
Scan Range : MIR 450-4000 cm-1  
Resolution : 1.0 cm-1  
Sample required : 50 mg, solid or liquid. 
 Fourier Transform Infrared Spectroscopy (FTIR) is an analytical technique 
used to identify mainly organic materials. FTIR analysis results in absorption spectra 
which provide information about the chemical bonds and molecular structure of a 
material. The FTIR spectrum is equivalent to the "fingerprint" of the material and can 
be compared with cataloged FTIR spectra to identify the material. 
Infrared spectrum is useful in identifying the functional groups like -OH, -CN, 
-CO, -CH, -NH2, etc. Also quantitative estimation is possible in certain cases for 
chemicals, pharmaceuticals, petroleum products, etc. Resins from industries, water 
and rubber samples can be analyzed.  
1.4(e) SCANNING ELECTRON MICROSCOPE (SEM): 
The Scanning Electron Microscope (SEM) is a microscope that was electrons 
rather than light to form an image. There are many advantages to using the SEM 
instead of a light microscope. 
Resolution  : 1.2 nm gold particle separation on a carbon substrate 
Magnification : From a min of 12 x to greater than 1, 00,000 X 
The SEM has a large depth of field, which allows a large amount of the 
sample to be in focus at one time. The SEM also produces images of high resolution, 
which means that closely spaced features can be examined at a high magnification. 
Preparation of the samples is relatively easy since most SEM one require the sample 
to be conductive. 
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The combination of higher magnification, larger depth of focus, greater 
resolution, and easy of sample observation marks the SEM one of the most heavily 
used instruments in research areas today. 
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2. TOXICOLOGICAL AND PHARMACOLOGICAL STUDIES 
Animals 
 Albino mice of either sex weighing 25-30g (For acute toxicity study) and 
Healthy Swiss Albino rats of the Wister strain weighing 150-200 g were used for the 
study. The animals were used with the approval of the Institute animal ethics 
committee and obtained from Vels University, Chennai. They were fed with a 
balanced standard pellet diet and maintained under standard laboratory conditions, 
providing 24-280C temperature, standard light cycle (12 h light, 12 h dark) and water 
ad libitum.  
 Animals were kept in cages with raised floors of wide mesh to prevent 
coprophagy. Animal welfare guidelines were observed during the maintenance period 
and experimentation. The rats were randomly assigned to control and different 
treatment groups, six animals per group. The experimental protocol used in this study 
was approved by IAEC. (XIII/VELS/PCOL/08/2000/CPCSEA/IAEC/08.08.2012). 
The animals were acclimatized for one week under laboratory conditions.  
Acute toxicity study: 
 Acute oral toxicity test for the Milakathi Chooranam was carried out as per 
OECD Guidelines 425. As with other sequential test designs, care was taken to ensure 
that animals are available in the appropriate size and age range for the entire study. 
The test substance is administered in a single dose by gavage using a stomach tube or 
a suitable intubation cannula. The fasted body weight of each animal is determined 
and the dose is calculated according to the body weight. After the substance has been 
administered, food was withheld for a further 2 hours in mice. Single animals are 
dosed in sequence usually at 48 h intervals.  
 However, the time interval between dosing is determined by the onset, 
duration, and severity of toxic signs. Treatment of an animal at the next dose was 
delayed until one is confident of survival of the previously dosed animal. The time 
interval was adjusted as appropriately in case of inconclusive response. The test is 
simpler to implement when a single time interval is used for making sequential dosing 
decisions. Special attention was given during the first 4 hours and daily thereafter, for 
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a total of 14 days, except where they need to be removed from the study and 
humanely killed for animal welfare reasons or are found dead.  
 All observations are systematically recorded and Observations include 
changes in skin and fur, eyes and mucous membranes, and also respiratory, 
circulatory, autonomic and central nervous systems, and somatomotor activity and 
behaviour pattern. Attention was directed to observations of tremors, convulsions, 
salivation, diarrhea, lethargy, sleep and coma. Animals found in a moribund condition 
and animals showing severe pain or enduring signs of severe distress was humanely 
killed. When animals are killed for humane reasons or found dead, the time of death 
was recorded 
SUB-ACUTE TOXICITY  
 In a 28-days sub acute toxicity study, twenty four either sex (3+3) rats were 
divided into four groups of 6 rats each. Group I that served as normal control was 
administered with distilled water (p.o.) while groups II, III and IV were administered 
daily with the Milakathi Chooranam (p.o.) for 28 days at a dose of 0.1, 0.2 and 
0.4g/kg respectively. The animals were then observed daily for gross behavioural 
changes and any other signs of subacute toxicity. The weight of each rat was recorded 
on day 0 and weekly throughout the course of the study, food and water consumption 
per rat was calculated. At the end of the 28 days they were fasted overnight, each 
animal was anaesthetized with diethylether, following which they were then dissected 
and blood samples were obtained by cardiac puncture into heparinised tubes. The 
blood sample collected from each rat was centrifuged with 3000 X g at 4oC for 10 min 
to separate the serum and used for the biochemical assays.  
Hematological and blood biochemical analyses:  
 At the end of the study, all animals were kept fasted for 16-18 h and then 
anesthetized with anesthetic ether on the 28th day. Blood samples for hematological 
and blood chemical analyses were taken from retro orbital vein. Heparinized blood 
samples were taken for determining complete blood count (white blood cell count, 
differential white blood cell count, platelet count, red blood cell count, hematocrit, 
and hemoglobin) by semiautomated hematology analyzer. The serum from non-
heparinized blood was carefully collected for blood chemistry and enzyme analysis 
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(glucose, creatinine, total protein, albumin, total and direct bilirubins, serum 
glutamate-oxaloacetate transaminase (SGOT), serum glutamate pyruvate 
transaminase (SGPT), and alkaline phosphatase (ALP)) were automatically 
determined using autoanalyzer. 
Necropsy:  
All rats were sacrificed after the blood collection. The positions, shapes, sizes and 
colors of internal organs were evaluated. The Spleen, Testes, Pancrea, Lung, Liver, 
Brain, Heart, Stomach, Intestine, Bone, Ovary, and Kidney tissues were excised from 
all rats to visually detect gross lesions, and weighed to determine relative organs’ 
weights and preserved in 10% neutral formalin for histopathological assessment. The 
tissues were embedded in paraffin, and then sectioned, stained with haematoxylin and 
eosin and were examined microscopically. 
Statistical analysis 
Values were represented as mean ± SEM. Data were analysed using one-way analysis 
of variance (ANOVA) and group means were compared using the Tukey-Kramer 
Multiple Comparisms Test using GraphPad Instat-V3 software. P values < 0.05 were 
considered significant. 
2.3 Screening the efficacy of Milagathy Choornam on Aspirin induced  Peptic 
ulcer rodents 
Procedure 
Aspirin induced Peptic ulcer: 
 Animals were divided into 5 groups (n = 6). Group I (Normal) treated with 
distilled water 5 ml/po. Group II (Control) treated with Carboxy methyl cellulose 
mixed with distilled water 5 ml/po. Group III (Test drug) treated with Milagathi 
Chooranam 250 mg/kg mixed with distilled water 5 ml/po and Group IV (Test drug) 
treated with Milagathi Chooranam 500 mg/kg mixed with distilled water 5 ml/po. 
Group V (Standard) treated with Ranitidine 60 mg/kg mixed with distilled water 5 
ml/po. All groups received treatment 30 min prior to the oral administration of aspirin 
(400mg/kg). The animals were scarified, after 6 hours following the administration of 
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aspirin, stomachs were removed and 2% formalin was injected into the stomach. The 
stomach was open along with greater curvature and immersed in 2% formalin 
solution.  
 The length of each lesion was measured under the dissecting microscope. The 
sum of the length (mm) of all lesions for each rat was used in lesion index. The ulcer 
score was determined by using a 10 × magnifying hand lens. The scoring of severity 
of ulceration was as follows: 1 mm (pin point) = 1; 1-2 mm = 2; > 2 mm = 3; > 3 mm 
= 4.  The mean ulcer score was determined by dividing the total ulcer indices in a 
group by the total number of animals in that group. Ulcer Score = Total ulcer index 
(UI) in a group/Total number of animals in that group.               
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3. CLINICAL STUDY OF MILAGATHI CHOORNAM 
3.1 Objectives 
`The study was conducted on hyperlipidemic patients to assess the 
hypolipidemic activity of “MILAGATHY CHOORANAM” clinically, both in-
patients and outpatients of both sex and varying age groups. 
3.2 Study Centre 
The clinical study for PEPTIC ULCER is carried out in outpatient 
department and in patient ward of Govt.Siddha medical college hospital and Arignar 
Anna Indian Hospital, Arumbakkam, Chennai-106. 
3.3 Design of the study: 
Open clinical trial, phase II B  
3.4 Selection: 
51 patients from both sexes of various age groups were selected for 
clinical trial. Among 50 patients, 40 patients were treated as out-patients, 11 patients 
were treated as in– patients. The selection was based on the including and excluding 
criteria. They were clinically diagnosed on the basis of siddha principles with modern 
laboratory findings. 
3.5 Registration Process 
To register a patient, the following document has been proceeded. 
¾ Copy of required laboratory tests 
¾ Signed patient consent form then I verified eligibility and assigned a patient 
study number, drug dose and registered the patient on the study. 
3.6 Selection Criteria: 
Inclusion Criteria: 
• Epigastric pain 
• Heart burn 
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• Regurgitation  
• Nausea/vomiting 
• Loss of appetite 
• Abdominal discomfort 
Exclusion Criteria: 
• Complication of peptic ulcer such as  
1. Haemorrhage,  
2. Perforation, 
3. Gastric outlet obstruction 
• Radiating abdominal pain as in pancreatitis, appendicitis 
• Acute abdominal colic’s 
• Cancer of the stomach  
• Gall stone and hiatus hernia  
• Cirrhosis of liver and jaundice 
3.7 Criteria for Withdrawal: 
Patients were removed from study when any of the criteria listed below 
applies. The reason for study removal and the date the patient was removed must be 
documented in the Case Report Form. 
• Irregular medication. 
• Patients who are all not cooperating to take blood samples. 
• Any adverse reactions during the study period. 
• Patients who are all not following the diet restrictions 
• Patient decides to withdraw from the study, or Unwanted prolonged illness 
during the study period 
3.8 Investigations: 
For all the cases full clinical data were recorded and they were diagnosed on 
the basis of SIDDHA principles i.e. Envagai Thrvugal, Ezhu Udal Thathukkal Etc. 
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All the patients under study were subjected to blood investigations for TC, 
DC, ESR, and Hb. 
Blood urea, serum cholesterol and Blood sugar were also investigated. 
 Urine test for albumin, sugar, deposits and motion test for ova, cysts were 
done. 
  The disease GUNMAM was confirmed in the patients by means of Endoscope 
examination, Barium meal examination and clinically. 
Administration of the drug: 
 Form of the medicine  : Chooranam 
Route of Administration : Enteral 
Dose  :  500 mg 
Anubanam (Vehicle)        : With food 
Diet and Medical Advice: 
Do’s and Don’ts: 
Do’s: 
• Timely food 
• Banana  
• Almond milk 
• Raw goat’s milk 
• Carrots and cabbage juice 
• Butter milk 
• He should chew every morsel thoroughly 
• Meals must be small and frequent 
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Dont’s 
• Intake of food stuff during stress and anxiety 
• Foods and drinks which are too hot or cold can be avoided 
• Spicy foods, carbonated drinks 
• Smoking and consumption of alcohol 
• Intake of steroids and NSAIDS. 
Follow up 
3.12 Trial Conduct: 
 This study will be conducted in compliance with the protocol approved by the 
Institutional Review Board, and according to Good Clinical Practice standards. No 
deviation from the protocol will be implemented without the prior review and 
approval of the IEC except where it may be necessary to eliminate an immediate 
hazard to a research subject. In such case, the deviation will be reported to the IEC as 
soon as possible. 
3.13 Criteria for Assessment of Response to Therapy: 
1) Marked Relief : 95% relief in signs and symptoms and marked 
normalcy of pathological investigations. 
2) Moderate Relief : 80% – 90% relief in the presenting signs and 
symptoms and moderate normalcy of pathological 
investigation. 
3) Mild Relief : 70% - 80% relief signs and symptoms, mild 
normalcy of pathological investigation. 
4) Poor Relief :    below 60% relief of signs and symptoms and no 
marked changes in pathological investigations. 
3.14 Ethical Review 
  The protocol and amendments were submitted to the Govt siddha medical 
college, Institutional Ethical Committee (IEC) and got formal approval for conducting 
the study. The decision of the IEC concerning the conduct of the study was made in 
writing to the investigator. 
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All subjects for this study was provided a consent form describing this study and 
provided sufficient information for subjects to make an informed decision about their 
participation in this study. This consent form was submitted with the protocol for 
review and approval by the IEC. The formal consent of a subject, using the IEC-
approved consent form, was obtained before that subject is submitted to any study 
procedure. This consent form was signed by the subject or legally acceptable 
surrogate, and the investigator-designated research professional obtaining the consent.   
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CHAPTER IV 
RESULTS AND DISCUSSION 
        The well documented Siddha herbo – mineral drug Milagathi choornam had 
been subjected to various studies to establish the works of Siddhars to be true. 
Literary collections, physicochemical and Phytochemical analysis, toxicological 
study, pharmacological study and clinical study are done to prove the anti – ulcer 
activity of  milagathi choornam. 
1. Finished form of Milakathi Choornam ( MC) 
The MC was prepared following strictly the method mentioned in the 
Siddha text. The finished MC gave positive results to all tests for Choornam as 
mentioned in Siddha Gunapadam literature. 
2. PHYSICO-CHEMICO ANALYSIS 
Table 1: Physicochemical parameters 
S.No Parameter Mean Value 
1.  Loss on Drying at 105°C 7.475 % 
2.  Total Ash  11.775 % 
3.  Acid insoluble Ash    0.175 % 
4.  Water Soluble Extractive 28.8 % 
5.  Alcohol Soluble Extractive 31.9 % 
6.  Particle size Completely passes through 
sieve no.44  
7.  pH 6.5 
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TLC analyses 
 
After spray with visualizing agent 
Sl.No After Dipping in Vanillin-Sulphuric acid 
 
Rf value Colour of the spot 
 
1 0.08 Purple 
2 0.20 Purple 
3 0.31 Yellow 
4 0.38 Purple 
5 0.58 Violet 
6 0.68 Purple 
7 0.77 Pink 
8 0.95 Purple 
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 The above result shows the presence of eight active compounds and at 0.38 Rf there 
is a higher concentration of active compound. This fingerprint may be used for 
standardization purpose in future.  
     FTIR RESULTS 
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These bands indicate the presence of amines, aldehydes, carboxylic acid, alkynes, and 
aromatic functional groups 
 
SCANNING ELCTRON MICROSCOPE (SEM) IMAGES 
 
 
The above plates indicates that all the particles are in nano level. This particle size 
makes. the choornam for better absorption. 
For drug delivery biodegradable nano particle formulations are needed as it is the 
intention to transport and release the drug in order to be effective. 
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TABLE 2: PHYTOCHEMICAL ANALYSIS OF MILAGATHI CHOORNAM             
Qualitative Phytochemical Tests 
1.  Alkaloids + ve 
2.  Anthraquinones - ve 
3.  Volatile oil + ve 
4.  Tannins + ve 
5.  Steroids   + ve 
6.  Saponin -  ve 
7.  Flavonoids + ve 
 
Phytochemical Analysis shows presence of alkaloids, volatile oil, flavonoids and 
steroids. 
Tannins are known to ‘ tan’ the outer most layer of the mucosa and to render it less 
permeable and more resistant to chemical and mechanical injury or irritation.(Asuzu 
and Onu  et al., 1990)  
Flavonoids have been found to be free radical scavengers. (Baumann et al., 1980). 
Free radicals play an important role in ulcerative an erosive lesions of the gastro 
intestinal tract. In relation to their low toxicity and to the properties reported, 
flavonoids could have a therapeutic potential ideal for treatment of gastro intestinal 
diseases associated with Helicobacter pylori infection i.e., type B gastritis and 
duodenal ulcer.( Di Carlo et al. 1999). 
Saponin increases the amount of glucose in ethanol -induced gastric ulceration. ( 
Marhuenda et al., 1994) 
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TABLE 3: PRELIMINARY CHEMICAL ANALYSIS OF Milagathi Choornam             
S.No. EXPERIMENT RESULT 
1 Reducing sugar - 
2 Starch - 
3 Protein - 
4 Amino acid - 
5 Albumin + 
6 Phosphate + 
7 Sulphate + 
8 Chloride + 
9 Iron + 
10 Calcium + 
11 Sodium - 
12 Potassium - 
13 Zinc - 
14 Magnesium - 
15 Alkaloids - 
16 Tannic acid + 
 
Chemical analysis of the MC shows the presence of tannic acid,calcium, 
iron,chloride,sulphate,phosphate,albumin. Tannic acid inhibits the gastric acid 
secretion in pylorous ligated rats and mice. ( Makato Muramatue et al., 1992). 
Phosphate is essential for formation of energy bonds like ATP, ADP. (Ambika 
shanmugam, Fundamentals of BioChemistry, page no.534) 
H.pylori infection was associated with a 40% increase in the prevalence of iron 
deficiency.(V.M Cardenes et al., 2005) 
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3. TOXICOLOGICAL AND PHARMACOLOGICAL STUDIES 
3.1 ACUTE TOXICITY PROFILE 
Table 4: Dose finding experiment and its behavioral Signs of Toxicity 
No 
Dose 
mg/k
g 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1 2000 + + - + + + - - - - - - - - - - - - - - 
2 5000 + + - + + + - - - - - - - + - - - - - - 
 
1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch 
Response 7. Decreased Motor Activity 8. Tremors 9. Convulsions 10. Muscle Spasm 
11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia 15.Lacrimation 16. 
Exophthalmos 17. Diarrhoea 18. Writhing 19. Respiration 20. Mortality 
 MC at the dose of 5000mg/kg/po did not exhibit mortality and did not show 
any signs of acute toxicity and significant behaviour changes. As per OECD 425 
guidelines, the median lethal dose is said to be more than 5000 mg/kg. 
Table 5. Body weight of rats in the toxicity study of the Milakathi Chooranam. 
Body Weight (g) Control MC 5000 mg/kg 
Day 0 174±10.2 182±10.1 
Day 7 178±5.9 185±12.1 
Day 14 181±11.2 188±12.5 
Mortality Nil Nil 
 
Results are expressed as mean ± S.E.M. n=6 
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3.2 SUB ACUTE TOXICITY PROFILE 
Animals were not shown any significant toxic clinical signs during the 
dosing period of 28 days. All animals from control and all the treated dose groups 
survived throughout the dosing period of 28 days. Results of body weight 
determination of animals of control and different dose groups exhibited comparable 
body weight gain but at the 100mg treated group showing significant body weight 
reduction after two weeks of treatment. During dosing period, the quantity of food 
consumed by animals from different dose groups was found to be comparable and 
normal with that of control animals. Ophthalmoscopic examination of animals in 
control and Milakathi Chooranam treated groups did not reveal any major and 
remarkable abnormality.  Results of Biochemical investigations revealed the values 
obtained were within normal biological and laboratory limits. The results of 
haematological investigations conducted on day 28, revealed increase in eosinophil 
and platelet level and decrease in monocyte at high dose group when compared to 
control; and the increase or decrease in the values obtained was within normal 
biological and laboratory limits.  
 Urine analysis data of control group and treated group of animals did not 
reveal any abnormalities. Comparison of organ weights of Milakathi Chooranam 
treated animals with respective control animals showed statistically significant weight 
gain in kidney (P<0.01) and lung (P<0.05) on day 28. Gross pathological examination 
of animals in control as well as the treated groups did not reveal any major 
abnormalities.  
 Based on the results obtained, it can be concluded that no significant toxic 
effect was observed upto 400mg/kg of Milakathi Chooranam treated via oral route 
over a period of 28 days. So, the Milakathi Chooranam can be prescribed for 
therapeutic use in human with the dosage recommendations of upto 400mg/kg. body 
weight p.o. 
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Table 6: Body weight changes of rats treated with Milakathi Chooranam during 
28 days of sub acute toxicity study 
 
Days 
Group 
Control Milakathi 
Chooranam 
100/kg 
Milakathi 
Chooranam 
200/kg 
Milakathi 
Chooranam 
400g/kg 
0 151.2±5.2 142.8±4.2 140.1±4.1 160.4±5.0 
7 154.4±4.4 142.1±5.1 142.3±4.0 162.2±4.5 
14 156.5±5.0 135.0±3.6** 145.6±3.2 164.0±4.0 
28 159.2±6.2 138.2±3.4* 148.2±4.2 166.2±4.8 
 
 The Data are expressed as mean ± S.E.M. Significant difference in each group 
versus the control were as follow *p<0.05, **P<0.01. 
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Table 7: Effect of Milakathi Chooranam on heamatological parameters after  
28 days treatment 
 
Parameter Normal  Milakathi 
Chooranam 
100/kg 
Milakathi 
Chooranam 
200/kg 
Milakathi 
Chooranam 
400g/kg 
RBC (millions/cu.mm) 5.10±0.43 5.12±0.34 5.20±0.32 5.42±0.40 
Hb (g/dl) 14.01±0.72 14.33±0.98 14.0±1.2 14.20±1.0 
PCV (%) 42.18±1.21 44.7±2.1 44.4±2.2 45.0±2.18 
WBC(cells/cu.mm) 7375±340 7250±334 7325±455 7633±510 
Neutrophil (%) 54.41±4.24 52.23 ±2.5 49.4±3.8 52.32±3.2 
Lymphocytes (%) 4.9±2.48 5.2±3.0 4.8±3.1 4.6±4.1 
Eosinophil’s (%) 4.0±0.42 5.1±0.51 5.4±0.44 5.63±0.40* 
Monocytes (%) 4.0±0.02 3.0±0.24** 4.0±0.3 2±0.1** 
Basophils (%) 0±0 0±0 0±0  0±0 
Platelet Count (105 
cells/cu.mm) 
1.72±0.05 1.80±0.04 1.84±0.05 2.0±0.08** 
MCV (Fl/red cell) 79.7±2.8 80.2±1.5 83.4±2.0 84.2±4.0 
MCHC (pg/red cell) 25.1±1.8 24.84±1.4 25.6±1.2 27.10±2.0 
 
Results are expressed as mean ± S.E.M. n=6; *P<0.05; **p<0.01 as compared to the 
control 
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Table 8: Effect of Milakathi Chooranam on Blood Chemistry values of rats after 
subacute toxicity study 
 
Results are expressed as mean ± S.E.M. n=6; nsP>0.05 as compared to the control. 
 
Parameter Control Milakathi Chooranam treated group 
200 mg/kg 400 mg/kg 
Glucose (mg/dL) 72.22±6.27 68.25±7.53 69.41±5.32 
Creatinine 
(mg/dL) 
0.90±0.06 0.87±0.05 0.93±0.03 
TB (mg/dL) 0.67±0.05 0.65±0.06 0.62±0.05 
AST (IU/L) 132.1±7.36 125±6.30 127.2±6.14 
ALT (IU/L) 37.13±3.52 32.12±2.75 30.10±2.21 
ALP (IU/L) 78.30±4.40 74.69±4.45 66.32±4.32 
TC (mg/dL) 56.72±5.22 55.05±5.52 55.74±5.12 
TP (g/dL) 8.18±0.20 7.89±0.20 7.48±0.72 
Albumin (g/dL) 2.64±0.07 2.75±0.07 2.72±0.06 
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Table 9: Urine Analysis 
Parameters 
Control Milakathi 
Chooranam 
100/kg 
Milakathi 
Chooranam 
200/kg 
Milakathi 
Chooranam 
400g/kg 
Colour Yellow Yellow Yellow Yellow 
Transparency Clear Slightly turbid Slightly 
cloudy 
Slightly turbid
Specific gravity 1.010 1.010 1.010 1.010 
PH >7.2 >8.0 >8.0 >9.0 
Protein Nil 3+ 3+ 3+ 
Glucose Nil Nil Nil Nil 
Bilirubin -ve -ve -ve -ve 
Ketones -ve +ve +ve +ve 
Blood Absent Absent Absent Absent 
Urobilinogen Normal Abnormal Abnormal Abnormal 
Pus cells 0-cells/HPF 1-cell/HPF 2-cells/HPF 1-cell/HPF 
RBCs Nil Nil 0-
1cells/HPF 
Nil 
Epithelial cells Nil 1-cell/HPF Nil 1-cell/HPF 
Crystals Nil Nil Nil Nil 
Casts Nil Nil Nil Nil 
Others Bacteria seen Bacteria seen Bacteria 
seen 
Bacteria seen 
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Table 10. Organ weight changes of rats in the sub acute toxicity study of the 
Milakathi Chooranam. 
Parameter Normal 
Control 
Milakathi 
Chooranam 
100/kg 
Milakathi 
Chooranam 
200/kg 
Milakathi 
Chooranam 
400g/kg 
Heart 0.35±0.02 0.37±0.02 0.34±0.01 0.35±0.02 
Liver 4.2±0.26 3.94±0.18 3.96±0.21 4.25±0.31 
Kidney 1.68±0.04 1.65±0.03 1.96±0.04** 1.77±0.05 
Lung 0.52±0.02 0.53±0.03 0.64±0.04* 0.58±0.03 
Brain 1.74±0.06 1.66±0.04 1.68±0.03 1.72±0.05 
 
Results are expressed as mean ± S.E.M. n=6; *P<0.05; **p<0.01 as compared to the 
control 
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3.3 PHARMACOLOGICAL EVALUATION OF MILAGATHI CHOORNAM 
 Ulcers are crater-like erosion or sore that occur in the upper gastrointestinal 
tract of the body. Stomach ulcers are also called peptic ulcers. The word peptic refers 
to pepsin, a stomach enzyme that breaks down protein. A peptic ulcer located in the 
stomach is called a gastric ulcer. An ulcer is the result of an imbalance between 
aggressive and defensive factors. On one hand, too much acid and pepsin can damage 
the stomach lining and cause ulceration. On the other hand, the damage comes first 
from some other cause making the stomach lining susceptible to even an ordinary 
level of gastric acid. Peptic ulceration is a very common disease and it is estimated 
that approximately 10%-20% of the adult male population in western countries will 
experience a peptic ulcer at some stage in their lives.  
 Peptic ulcer is a benign lesion of gastric or duodenal mucosa occurring at a 
site where the mucosal epithelium is exposed to acid and pepsin. There is constant 
confrontation in the stomach and upper small bowel between acid-pepsin aggression 
and mucosal defense. Usually, the mucosa can withstand the acid-pepsin attack and 
remain healthy. That is, a mucosal ‘‘barrier’’ to back diffusion of acid is maintained. 
However, an excess of acid production or an intrinsic defect in the barrier functions of 
the mucosa can allow the defense mechanism to fail and ulcer to result. Since it’s 
recognition of the peptic ulcer as an important chemical entity, various efforts have 
been made to find suitable remedial measures. For several decades the adage ‘‘no 
acid-no ulcer’’ and the drugs used to reduce acid secretion have dominated the 
pharmacological basis of ulcer therapy. It is now well established that peptic ulcer 
disease can be prevented by strengthening the defensive mechanisms of gastric and 
duodenal mucosa rather than attenuating factors of aggression causing ulceration. 
Histopathology of stomach show that test drug Milagathi Chooranam 
500 mg/kg significantly reduced gastric lesion formation and sub-mucosal edema 
similar to the ranitidine treated animals but it was not remarkable as standard drug 
treated group. Careful evaluation revealed that the mucosa of ulcer control animals 
have hemorrhagic erosion, discontinuity in the lining of epithelium cells and 
significant damage in sub-mucosa.  
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 Normal mucosa with small strophic gland, mild hyperplasia and no edema 
were observed for animals treated with ranitidine. Similarly, the effect was moderate 
at the lower dose. Mucosa of animals treated with Milakathi Chooranam 250mg/kg 
was identified with hemorrhagic erosion, discontinuity in the lining of epithelium 
cells and significant damage in sub-mucosal layer. Thus our study reveals that the 
significant antiulcer effect of Milakathi Chooranam. However, further studies are 
required to establish its exact mode of action and the active principles involved in its 
anti-ulcer effect. 
From this study, it is clearly evident that Milakathi Chooranam have 
significant action as anti-ulcer activity in animal models at the dose levels of 250 and 
500mg/kg-1. 
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HIOSTOTATHALOGICAL  PICTURES   
BONES 
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Table 11 — Effect of Milakathi Chooranam on ulcer index 
Groups  Ulcer index 
Normal 1.25±0.08 
CMC control  24.19 ± 0.26 
MC (250mg/kg) 19.64 ± 
0.22**,b 
MC (500mg/kg) 14.26 ± 
0.18**,b 
Ranitidine (60mg/kg) 10.34 ± 
0.15**,b 
Values are the mean ± S.E.M. (n=6). 
Significance *p <0.05, **p<0.01 Vs Control.; bp<0.01 Vs Standard 
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Table No.4.5.1 
Gradation result 
SL. NO LEVEL OF 
IMPROVEMENT 
NO.OF 
PATIENTS 
PERCENTAGE (%) 
1 Marked Responese 39 76 
2 Moderate Responese 6 12 
3 Mild Responese 4 8 
4 Poor Responese 2 4 
TOTAL 51 100 
 
 
Inference: 
Among 51 patients, 
• 39 patients had marked response. 
• 6 patients had moderate respone. 
• 4 patients had mild response. 
• 2 patients had poor response. 
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Table NO.4.5.2 
Improvement In Signs And Symptoms 
SL.NO 
SIGNS AND 
SYMPTOMS 
No of Patients 
BT AT IMP IMP % 
1 Epigastric  Pain 48 5 43 90 
2 Feeling of fullness 30 5 25 83 
3 Hunger Pain 20 3 17 85 
4 Heart Burn 45 3 42 93 
5 Water Brash 30 3 27 90 
6 Regurgitation 42 2 40 95 
7 Nausea 25 2 23 92 
8 Vomiting 8 2 6 75 
9 Constipation 15 3 12 80 
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Inference: 
Among 51 patients, 
43 out of 48 relieved from epigastric pain 27 out of 30 relieved from 
water brash 
25 out of 30 relieved from feeling of fullness   40 out of 42 relieved from 
regurgitation 
17 out of 20 relieved from hunger pain  23 out of 25 relieved from nausea 
42 out of 45 relieved from heart burn  12 out of 15 relieved from 
constipation 
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SUMMARY 
Herbo- mineral drug Milagathi choornam was prepared as per Siddha classical 
way and its efficacy on peptic ulcer was evaluated. 
The literary review in Siddha and modern aspect are discussed thoroughly and 
the valuation of drug had been established. 
Studies involving phytochemical, chemical, elemental and physio chemical 
analysis   are done to make its efficiency more visible. 
The pharmacological analysis showed that the drug has got significant Anti 
ulcer activity with cytoprotective mechanism. 
In clinical study the drug has showed 76% marked response to peptic ulcer. 
This present study confirms that Milagathi choornam has remarkable Anti 
ulcer activity and prooves the words written in Siddha literature are evergreen. 
The trial drug was duely identified and authenticated by the gunapadam 
experts. The literary reviews along with Phytochemical, chemical constituents, 
elemental analysis supports the efficient activity of the drug, Standardisation of the 
drug was done by physio chemical analysis. 
   Presence of flavanoids, alkaloids, saponins, tannins, helps in healing ulcer. 
  Presence of Tannic acid, chloride, Calcium, Ferrous, Phosphate, and sulphate 
aids in mucosal protection and heals ulcer.  
Through above supportive theories of Milagathi choornam, it can be concluded that 
the drug throw new light on Siddha system and Peptic ulcer disease 
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CONCLUSION 
Inspite of long usage of Milakathi choornam in our Siddha medicine, no 
evidences in safety and therapeutic applications are not documented yet. These studies 
pave the pathway in validation of MC in the treatment of Peptic Ulcer and make the 
scientific communities to believe the Siddha medicine. 
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